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Abstract 
Protective immunity upon vaccination is the result of complex and concerted cascades of biological events 
leading up to a multitude of adaptive immune responses that traditionally protect the vaccinees from 
infectious and toxicological danger of pathogens. Alternatively, the goal of vaccination is to generate immune 
responses for therapeutic treatment of established conditions, e.g. allergy and cancer. The immunity is 
believed to require the close cooperation of T- and B-lymphocytes and to be dependent on major 
histocompatibility complex (MHC)-restricted antigen presentation through antigen-presenting cells (APCs) 
e.g. dendritic cells and macrophages. APCs recognize antigens in tissues, process them and present the 
fragments in the context of MHC class I to CD8 T cells for induction of cytotoxic (CTL) responses, or in the 
context of MHC class II to CD4 T cells for subsequent B-cell activation. In response to peptide or protein 
antigens, CD4 T-helper (TH) cells are generally required for B-cell activation and differentiation into memory 
cells, and for immunoglobulin class switching from IgM to IgG, IgA, and IgE. Current prophylactic vaccines 
primarily elicit memory B-cell responses protecting from pathogens by means of neutralizing antibodies. 
Allergen immunotherapy (AIT) is thought to involve antibodies, as well as TH cells and regulatory CD4 T cells 
(Tregs), while the primary aim of cancer immunotherapy is to trigger MHC class I-restricted CTL responses as 
well as bystander MHC class II-restricted TH-type 1 immune responses. Adjuvants and vaccine delivery 
systems enhance immune responses and have the potential to trigger specific immune responses required 
for protection or effective therapy. However, achieving such stimulation requires an understanding of how 
immunostimulators mediate their immunogenicity. Hence, the objective of this PhD thesis was to investigate 
the possibilities and limitations in immune-response induction with vaccines and by using liposomes, to fool 
the default pattern of immune-response induction and possibly pave the way for new vaccination or 
immunotherapeutic strategies. 
Liposomal vaccine preparations were developed, produced, and tested in mice for their suitability to target 
antigen and adjuvant directly to B cells for stimulation of class-switched antibody responses independent on 
T-cell help. The T-cell independent (TI) vaccine was used as a tool to study the requirement for T cells in AIT. 
Alternatively, liposomes were fabricated to contain antigen and a photosensitizer for delivery of the antigen 
to the cytosol of APCs for stimulation of MHC class I-restricted CD8 T-cells. Finally, the delivery of 
immunotherapeutic antigen for AIT was achieved by routing a conventional aluminum-based allergy vaccine 
directly to the lymph nodes. Specifically, effects of AIT dosing intervals on the treatment efficacy were 
investigated. 
Immunization of mice with liposomes loaded with a 15mer ovalbumin (OVA) peptide and monophosphoryl 
lipid A (MPLA), elicited TI IgG class switch and germinal center formation. The long-lasting antibody responses 
displayed characteristics of both TI-1, strictly dependent on TLR4 signaling through MyD88, and TI-2, partially 
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dependent on BTK signal transmission. Secondary immunization three months after the primary 
immunization caused a boost of all IgG subclasses. This is the first demonstration of antibody response with 
characteristics of both TI-1 and TI-2 type response as well as of a T-cell independent endogenous B-cell 
memory response in vivo using a peptide antigen. When the liposomal vaccine was used in a mouse model 
of AIT, the induced antibody responses did not protect OVA-sensitized mice from systemic anaphylaxis. 
However, the TI antibodies had neutralizing effects in prophylactic models of allergy and infection. When 
liposomes were used for targeting of the MHC class-I pathway of antigen presentation and for stimulation of 
CD8 T-cell responses, the combination with the photosensitizer disulfonated tetraphenyl chlorine (TPCS2a) 
and light treatment successfully shifted antigen processing from MHC II to MHC I, and presentation was 
enabled for stimulation of strong CD8 T-cell responses. Consequently, the MHC class II-dependent antibody 
responses were reduced in mice treated with TPCS2a-containing liposomes as compared with TPCS2a-free 
liposomes. Finally, when mice were sensitized to OVA and given intralymphatic immunotherapy (ILIT) with 
the OVA protein with 1, 2, and 4 week intervals, immunogenicity testing and tests of protection against 
allergic anaphylaxis suggested that longer dosing intervals improved treatment and increase both serum 
levels of protective IgG2a antibodies and their avidity. 
In conclusion, liposomes could be successfully utilized to target B cells directly for stimulation of TI antibody 
responses and in a second strategy to target the MHC class-I pathway of antigen presentation for stimulation 
of CD8 T-cell responses. Hence, as a platform for antigen delivery, liposomes can serve very different 
purposes, for which reason liposomes may likely find utilization in variety of future vaccines or 
immunotherapies. For instance, TI vaccines may be proven beneficial for vaccination of immunosuppressed 
individuals, in conditions where T-cell activation has unwanted adverse effects, or during infectious 
outbreaks when rapid vaccination coverage and immune protection is needed. Furthermore, formulating 
photosensitizer in liposomes has the potential to bypass the default MHC class-II antigen presentation of 
vaccines antigens. The resulting stimulation of cytotoxic CD8 T-cell responses may find utilization in cancer 
immunotherapy or therapeutic vaccination against infections caused by intracellular pathogens that are not 
sensitive to and reached by antibodies. Finally, therapy intervals in ILIT affect the immunogenicity and 
treatment efficacy in mice and should be considered in clinical research and practice. 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung 
Schutzimmunität bei der Impfung ist das Ergebnis von komplexen und aufeinander abgestimmten Kaskaden 
von biologischen Ereignissen, welche zu einer Vielzahl von adaptiven Immunantworten führen und somit die 
Impflinge vor einer infektiösen und toxikologischen Gefahr durch Pathogene schützt. Alternativ besteht das 
Ziel einer Impfung darin, Immunantworten zur therapeutischen Behandlung etablierter Zustände zu 
erzeugen, z.B. bei Allergien und Krebs. Es wird angenommen, dass die Immunität die enge Kooperation von 
T- und B-Lymphozyten erfordert und dass sie abhängig ist von der Antigenpräsentation des 
Haupthistokompatibilitätskomplexes (MHC) via Antigen-präsentierende Zellen (APCs), wie z.B. dendritische 
Zellen und Makrophagen. APCs erkennen Antigene in Geweben, prozessieren sie und präsentieren die 
Fragmente im Falle von MHC Klasse I den CD8 T-Zellen zur Induktion von zytotoxischen (CTL) Antworten oder 
im Falle von MHC Klasse II den CD4 T-Zellen für eine nachfolgende B-Zell-Aktivierung. Als Antwort auf Peptid- 
oder Proteinantigene werden CD4-T-Helferzellen (TH) im Allgemeinen für die B-Zell-Aktivierung und -
Differenzierung in Gedächtniszellen sowie für die Immunglobulinklassenwechsel von IgM zu IgG, IgA, und IgE 
benötigt. Gegenwärtige prophylaktische Impfstoffe rufen hauptsächlich Gedächtnis-B-Zell-Antworten 
hervor, die mittels neutralisierender Antikörper vor Krankheitserregern schützen. Es wird angenommen, dass 
die Allergen-Immuntherapie (AIT) sowohl Antikörper als auch TH-Zellen und regulatorische CD4-T-Zellen 
(Tregs) involviert, während das primäre Ziel der Krebs-Immuntherapie die Induktion von MHC-Klasse-I-
restringierten CTL-Antworten sowie „bystander“-MHC-Klasse II-restringierten TH-Typ-1 Immunantworten ist. 
Adjuvantien und Impfstoffabgabesysteme verbessern die Immunantwort und haben das Potenzial, 
spezifische Immunantworten auszulösen, die für den Schutz oder eine wirksame Therapie erforderlich sind. 
Um eine solche Stimulation zu erreichen, muss jedoch verstanden werden, wie Immunstimulatoren ihre 
Immunogenität vermitteln. Das Ziel dieser Doktorarbeit war es daher, Möglichkeiten und Grenzen der 
Immunantwort-Induzierung mit Impfstoffen und mithilfe von Liposomen zu untersuchen, um Standard-
Muster der Immunantwort-Induzierung zu täuschen und möglicherweise auch den Weg für neue Impfungen 
oder für immuntherapeutische Strategien zu eröffnen. 
Liposomale Impfstoffpräparate wurden entwickelt, hergestellt und in Mäusen auf ihre Eignung, ob sich 
Antigen und Adjuvans direkt an B-Zellen zur T-Zell-unabhängigen Stimulierung von klassengewechselten 
Antikörperantworten richten, getestet. Der T-Zell-unabhängige (TI) Impfstoff wurde als ein Werkzeug 
verwendet, um den Bedarf an T-Zellen in AIT zu untersuchen. Alternativ dazu wurden Liposomen mit einem 
Antigen und einem Photosensibilisator, zur Abgabe des Antigens in das Cytosol von APCs, hergestellt, um die 
MHC-Klasse-I-restringierten CD8-T-Zellen zu stimulieren. Schließlich wurde die Verabreichung vom 
immuntherapeutischen Antigen für AIT erreicht, indem ein herkömmlicher, auf Aluminium-basierender 
Allergie-Impfstoff direkt zu den Lymphknoten geleitet wurde. Insbesondere wurde die Auswirkung der AIT-
Dosierungsintervalle auf die Wirksamkeit der Behandlung untersucht. 
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Die Immunisierung von Mäusen mit Liposomen, die mit einem 15-mer-Ovalbumin (OVA) -Peptid und einem 
Monophosphoryl-Lipid A (MPLA) beladen waren, rief einen TI-IgG-Klassenwechsel und eine 
Keimzentrumsbildung hervor. Die langanhaltenden Antikörperantworten zeigten Eigenschaften von TI-1, 
streng abhängigvon der TLR4-Signalisierung durch MyD88, und von TI-2, teilweise abhängig von der BTK-
Signalübertragung. Die sekundäre Immunisierung, welche drei Monate nach der Primärimmunisierung 
durchgeführt wurde, verursachte einen Anstieg aller IgG-Subklassen. Dies ist der erste in vivo-Nachweis einer 
Antikörperantwort mit Charakteristika vom TI-1- und TI-2-Typ sowie von einer T-Zell-unabhängigen 
endogenen B-Zell-Gedächtnisantwort unter Anwendung eines Peptidantigens. Als der liposomale Impfstoff 
in einem Mausmodell von AIT verwendet wurde, schützten die induzierten Antikörperreaktionen die OVA-
sensibilisierten Mäuse nicht vor einer systemischen Anaphylaxie. Die TI-Antikörper zeigten jedoch 
neutralisierende Effekte in prophylaktischen Allergie- und Infektions-Modellen. Wenn die Liposomen zum 
Targeting des MHC-Klasse-I-Weges der Antigenpräsentation und zur Stimulierung von CD8-T-Zellantworten 
verwendet wurden, verlagerte die Kombination mit dem Photosensibilisator disulfonierter Tetraphenylchlor 
(TPCS2a) und eine Lichtbehandlung die Antigenverarbeitung von MHC II zu MHC I und die Präsentation 
ermöglichte die Stimulierung von starken CD8-T-Zellantworten. Folglich waren die MHC-Klasse-II-abhängigen 
Antikörperreaktionen in Mäusen, die mit TPCS2a-enthaltenden Liposomen behandelt wurden, reduziert im 
Vergleich zu TPCS2a-freien Liposomen. Schließlich, wenn Mäuse für OVA sensibilisiert und ihnen eine 
intralymphatische Immuntherapie (ILIT) mit dem OVA-Protein in 1, 2 und 4 Wochen-Intervallen gegeben 
wurde, zeigten Immunogenitätstests und Tests zur Evaluierung des Schutzes gegen allergische Anaphylaxie, 
dass längere Dosierungsintervalle die Behandlung verbessern und die Serumspiegel von schützenden IgG2a-
Antikörpern und deren Avidität erhöhen. 
Zusammenfassend kann gesagt werden, dass Liposome erfolgreich zur Stimulierung von TI-
Antikörperantworten via das Targeting von B-Zellen verwendet werden können. Weiter kann 
geschlussfolgert werden, dass Liposome verwendet werden können, um den MHC-Klasse-I-Weg der 
Antigenpräsentation zur Stimulierung von CD8-T-Zellantworten anzusteuern. Daher können Liposome als 
Medium zur Antigenbeförderung sehr unterschiedliche Zwecke erfüllen, weshalb Liposome in einer Vielzahl 
von zukünftigen Impfstoffen oder Immuntherapien Verwendung finden könnten. Zum Beispiel können TI-
Impfstoffe zur Impfung immunsupprimierter Individuen vorteilhaft sein unter Bedingungen, bei denen eine 
T-Zell-Aktivierung unerwünschte Effekte hat, oder während infektiösen Ausbrüchen, wenn eine schnelle 
Durchimpfung und Immunschutz erforderlich ist. Darüber hinaus hat die Hinzugabe von 
Photosensibilisatoren in Liposomen das Potential, die Standard-MHC-Klasse-II-Antigenpräsentation von 
Impfantigenen zu umgehen. Die resultierende Stimulation von zytotoxischen CD8-T-Zellantworten kann in 
der Krebsimmuntherapie oder in der therapeutischen Impfung gegen Infektionen, die durch intrazelluläre 
 
 
 
 
 
 
 
 
Pathogene verursacht werden und die gegenüber Antikörpern unempfindlich sind respektive von diesen 
nicht erreicht werden, Verwendung finden. Abschließend beeinflussen Therapieintervalle in ILIT die 
Immunogenität und Behandlungseffizienz bei Mäusen, welches in klinischen Forschung und Praxis 
berücksichtigt werden sollte. 
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General introduction 
B lymphocytes 
B lymphocytes are important players in the adaptive immune system and precursors of antibody 
secreting cells [1]. Mature, naïve B cells are divided into distinct subsets, B-1 cells and conventional B-
2 cells, the latter consisting of follicular B cells and marginal zone (MZ) B cells [2]. Follicular B cells are 
located in the follicles of secondary lymphoid organs such as the lymph nodes and spleen, but can 
circulate through the blood and lymph. They mainly participate in T-cell dependent (TD) immune 
responses to protein antigens [3]. MZ B cells are a mixed population of naïve B cells and memory B 
cells that occupy the splenic marginal zone between the marginal sinus and the red pulp, where these 
B cells recognize and bind to blood-borne particulate pathogens [4, 5]. In response to T-cell 
independent (TI) antigens, MZ B cells mediate rapid protection by differentiating into short-lived 
extrafollicular plasma cells [6, 7]. B-1 cells are located in pleural and peritoneal cavities and are found 
in small numbers in secondary lymphoid tissues. B-1 cells can be divided into B-1a, a component of 
innate defenses expressing CD5, and B-1b cells, which along with MZ B cells respond to TI antigens [8, 
9]. B-1b cells also differentiate into extrafollicular plasma cells in a TI manner and have been shown to 
give rise to TI memory B cells [10] and long-lived memory plasma cells [8]. MZ B cells and B-1 cells have 
a lower activation threshold and rapidly differentiate into plasma cells, rendering the onset of TI 
antibody responses faster than TD responses, which is critical for controlling blood-borne infections 
[4, 11]. MZ and B-1 cells undergo positive selection based on their B-cell receptor (BCR) recognition of 
components of the microbial flora and self-antigens, while self-reactive follicular B cells are eradicated 
during their development [8]. 
Activation of humoral immune responses 
High numbers of T and B cells accumulate and circulate in the secondary lymphoid tissues [12], a highly 
immunocompetent environment where antigen-presenting cells (APCs), such as macrophages, 
dendritic cells (DCs), and lymphocytes are brought together to initiate adaptive immune responses 
[13]. The close proximity of those cells allows for very efficient antigen presentation, costimulatory 
signaling, and bystander effects, leading to activation of T and B cells [12]. The lymph nodes have a 
profoundly organized structure, and a constant stream of lymph is delivered via the afferent lymphatic 
vessel and flows through the lymph node before draining into the efferent lymphatic vessel. This 
process allows for exposure to antigens, APCs, and inflammatory mediators collected in the lymph 
[14]. The entire lymph node is organized within a porous tissue composed of fibroblastic reticular cells, 
dividing it into narrow channels, providing spaces for APCs and lymphocytes to meet. Lymph nodes 
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have defined compartments for lymphocytes, with B cells homing to primary follicles where they 
survey follicular dendritic cells (FDCs) while T cells home to the paracortex and interfollicular cortex to 
survey DCs [15]. 
APCs collect antigens from tissues, internalize them and degrade to peptide fragments that can bind 
to major histocompatibility complex (MHC) class II molecules, and be presented on the cell surface. 
When APCs have sampled antigens in the peripheral tissues, they are transported in lymph to draining 
lymph nodes, while losing their ability to collect antigen and gaining the ability to present antigen to 
CD4 T cells [16, 17]. T cells make frequent contact with APCs before finding their specific antigen 
displayed. When the T cells encounter APCs displaying cognate antigen on MHC class II molecules, the 
T cells become activated and migrate to T-cell zones in secondary lymphoid organs [1, 18, 19]. 
B cells recognize protein antigens through their BCR while circulating in the blood. In the following, the 
B cells migrate to the interface of the T-cell zone and to the B-cell follicle in secondary lymphoid organs 
[17]. Additionally, B cells can recognize antigens presented on FDCs in primary and secondary follicles 
[15]. The B cells require two signals for activation of humoral responses (Fig. 1A). The first signal comes 
through the BCR and the second from activated antigen-specific CD4 T-helper (TH) cells [20-22]. The TH 
cells recognize the MHC class II-bound antigen on the B cells [22] and provide the second signal through 
costimulatory molecules, such as CD40, and inflammatory cytokines, such as interleukin 2 (IL-2), IL-4, 
IL-5, IL-6, IL-10, IL-21 and interferon (IFN) ɣ [1, 9, 19, 23, 24]. These signals promote B-cell proliferation, 
immunoglobulin (Ig) class switching and differentiation of B cells into short-lived extrafollicular plasma 
cells (PCs), early memory B cells, or germinal center (GC) B cells [9, 24-27]. 
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B-cell activation independent on T cell help 
Non-protein antigens can stimulate B cells to 
produce antibodies in the absence of TH cells. Such 
TI antibody responses have been categorized based 
on their dependence on the cytoplasmic enzyme 
Bruton’s tyrosine kinase (BTK) [28, 29]. Type 1 TI (TI-
1) antigens (Fig. 1B) are able to elicit antibody 
responses in the absence of BTK, but require Toll-
like receptor (TLR) signaling, whereas type 2 (TI-2) 
antigens (Fig. 1C) are fully dependent on BTK [9]. 
While TI-1 antigens are molecular structures specific 
for microbial pathogens such as lipopeptides, 
lipopolysaccharides (LPS), and microbial nucleic 
acids that provide required second signal through 
TLRs [30], TI-2 antigens are highly repetitive 
structures of polyvalent antigens such as bacterial 
capsular polysaccharides or viral surface proteins 
[31]. Through extensive crosslinking of BCRs with TI-
2 antigens, BTK transmits sufficiently strong signals 
and thereby bypasses the need of further co-
stimulatory signals [28].  
Germinal centers and B-cell memory 
Activated, proliferating B cells form GCs in follicles of secondary lymphoid organs [32]. GCs are the 
sites where affinity maturation of antibodies takes place by somatic hypermutation (SHM) of the genes 
encoding the immunoglobulin variable region [33, 34]. Furthermore, the immunoglobulin isotype and 
effector function is determined by class-switch recombination (CSR) of the genes encoding the 
constant region [32]. Germinal centers form around six days after the first antigen encounter [35, 36]. 
The GC reaction peaks on days 7-10 [37], and if antigen is cleared, the GC remains for 2-3 weeks before 
the structure slowly involutes and disappears [25, 32, 38]. 
Activation of B cells by TH cells causes the expression of the transcription repressor Bcl6  and results in 
proliferation and differentiation of B cells into GC centroblasts [32, 39]. Centroblasts form the dark 
zone of the GCs, proximal to the T-cell zone (Fig. 2), where the centroblasts undergo clonal expansion 
 
Figure 1: Classification of B-cell activation by 
sources of the second stimulatory signal. A)  In T-
cell dependent (TD) activation of B cells the 
second activation signal comes through CD40-
CD40L ligation from CD4 T-helper cells after 
binding of their T-cell receptor (TCR) to antigen 
presented on the MHC class II molecule. B) In type 
1 T-cell independent (TI-1) activation the second 
signal is provided by microbial ligands through 
Toll-like receptors (TLRs). C) In TI-2 activation 
polyvalent antigens transmit a strong signal 
through B-cell receptor crosslinking. 
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and SHM. After successful affinity maturation, the centroblasts home to the GC light zone as smaller, 
non-dividing centrocytes. In the light zone, the centrocytes mix with a dense network of FDCs, follicular 
T-helper (TFH) cells, and macrophages [32, 35, 40]. Expressing newly mutated antibodies, the 
centrocytes are able to bind antigen on FDCs for presentation to TFH cells, from which they receive 
survival and selection signals. These signals are typically mediated through CD40L, PD-1, and BAFF, or 
provided by IL-4, IL-10, and IL-21 [9, 19, 23, 41], and the signals stimulate CSR and differentiation to 
long-lived PCs and memory B cells [42-44]. Whether the centrocytes are selected to become PCs or 
memory B cells is controlled by the antigen affinity. Higher affinity centrocytes differentiate to PCs, 
and those of lower affinity migrate to the MZ and perifollicular areas as memory B cells [45-47]. 
Moreover, the interaction of centrocytes and TFH cells perpetuates GC reactions by stimulating 
centrocytes to home back to the dark zone. Here, the centrocytes again become centroblasts and can 
undergo further SHM. If SHM produces unfavorable antibodies and the centrocytes are unable to bind 
antigen on FDCs for presentation to TFH cells, the centrocytes undergo apoptosis. Similarly, in the 
absence of TFH cells, the B cells undergo apoptosis, and the GC are abrogated early after induction [25, 
40]. Real-time pictures of the GC reaction have demonstrated that B cells move constantly through the 
GC and engage in brief but dynamic interactions with both T cells and antigens [40, 48-50]. 
 
Figure 2: The germinal center (GC) 
microenvironment. Antigen-activated B 
cells differentiate into centroblasts that 
undergo clonal expansion (proliferation) in 
the dark zone of the GC. During proliferation, 
the process of somatic hypermutation (SHM) 
takes place. Centroblasts then differentiate 
into centrocytes and move to the light zone, 
where the modified antigen receptor is 
selected for improved binding to antigen on 
follicular dendritic cells (FDC) and 
presentation to follicular T-helper (TFH) cells. 
Subsets of centrocytes undergo class-switch 
recombination (CSR) or cycle back into the 
dark zone for further SHM. Centrocytes 
producing unfacourable antibodies undergo 
apoptosis and are removed. Eventually, 
antigen-selected centrocytes differentiate 
into memory B cells or plasma cells. 
 
 
 
Chapter  1
 
16 
Contrary to previous understanding, newer studies suggest that short-lived GCs can form in the 
absence of T cells; these studies were performed using the antigen construct of nitrophenyl conjugated 
to polysaccharide (NP-Ficoll) [51-53]. In part, the GC formation was obtained using transgenic 
quasimonoclonal (QM) mice, with high numbers of antigen-specific B-cell precursors with a uniform 
high affinity for NP [52, 53]. When formed in T-cell deficient mice, the GCs were small with no SHM 
taking place [51]. In transgenic QM mice, low mutation rates were observed in TI GCs and even in 
extrafollicular PCs [53]. Hypermutation was not seen in response to NP-Ficoll in wild-type mice [54], so 
the observed SHM might be a result of the unnatural strong signaling obtained in transgenic QM mice.  
GCs induced with NP-Ficoll were detected two days after immunization and were gone six days after 
immunization [52]. In contrast, T cells are not needed in T-cell dependent GC formation until the stage 
of centrocyte selection in the light zone (Fig. 2), approximately on day 6, after which a proportion of 
positively selected centrocytes cycles back into the dark zone, as centroblasts, for further SHM. The 
centroblasts likely undergo a finite number of divisions before they mature into centrocytes, in which 
case the pool of centroblasts can run out unless it is renewed [55]. The lack of centrocyte renewal in 
the absence of positive selection by TFH cells may explain the sudden termination of the T-cell 
independent GC reaction, as the GC collapses by massive B-cell apoptosis a few hours after the 
formation of the dark and light zones [53]. 
Until recently, TI antigens were assumed unable to induce B-cell memory because accelerated, 
amplified, and affinity maturated antibody production upon secondary immunization had not been 
observed [8]. B-cell memory without T-cell involvement was first shown in the late seventies when 
memory formation was demonstrated in response to haptenated TI antigens [56, 57]. However, recall 
antibody responses could only be obtained when primed B cells were adoptively transferred to naïve 
recipients before the secondary challenge with antigen [56, 58-60]. The concept of TI memory was 
revisited in 2004 showing that long-lived anti-bacterial humoral immunity can be generated without 
T-cell help [10]. The results revealed that IgM-secreting B-1b cells from both wild type and T-cell 
deficient donors, that had cleared a B. hermsii infection, could control bacterial infection in Rag1-/- 
mice. The existence of TI memory B cells to NP-Ficoll was confirmed in the only study that has described 
phenotypical and functional features of TI memory B cells [61], while direct B-cell memory has only 
been shown in mouse models of B-cell transfer [8]. Although not proving B-cell memory, clinical 
vaccination with an anti-pneumococcal vaccine composed of purified TI-2 polysaccharide antigens 
from S. pneumoniae stimulated protective humoral immunity in adults [62, 63] that lasted for years 
[64]. Since the half-life of immunoglobulins are typically weeks, these clinical results suggest that 
functional memory can be obtained even with TI-2 antigens. 
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In contrast to B-cell memory to TD antigens, the memory induced by TI antigens is suppressed by 
injecting immune serum in naïve recipients before the adoptive transfer [59, 60]. TI B-cell memory has 
been found to be tightly regulated through negative feedback by antigen-specific antibodies [59, 61]. 
This negative feedback on memory B-cell responses could be a part in self-tolerance [8] or a 
suppressive mechanism to avoid antibody over production and to maintain humoral homeostasis [61]. 
If the TI memory B cells are so tightly controlled, how do they protect upon secondary infection? TI-2 
antigens elicit strong and long-lasting primary extrafollicular antibody response in mice [31]. In TD 
responses it has been established that a second memory compartment, consisting of long-lived bone 
marrow (BM) PCs, is generated in addition to memory B cells [65, 66]. The BM PCs have been believed 
to be strictly T-cell dependent and require formation of GCs [67]. Yet, the TI-2 antigen S. pneumoniae 
capsular polysaccharide generated long-lived BM PCs secreting protective IgM and IgG [62]. 
Nonetheless, the PCs generated by TD and TI antigens are functionally different, suggesting that the 
memory PC compartment is heterogeneous [62]. It is unclear when the memory compartment comes 
into play upon secondary exposure to antigen, and the contribution of TI memory B cells and TI 
memory PCs may vary depending on antigen type and persistence as well as the route of antigen entry. 
Immunoglobulins 
Immunoglobulins are heterodimeric 
glycoproteins [68] that serve two 
purposes. Firstly, immunoglobulins are 
cell-surface receptors for antigens on B 
cells, permitting and transforming cell 
signaling that leads to B-cell activation and 
antibody production. Secondly, 
immunoglobulins are soluble antibodies, 
capable of binding and neutralizing 
antigens [69]. The immunoglobulin 
molecule is composed of three major 
fragments, two Fab fragments and the Fc 
fragment, consisting of two heavy chains 
and two light chains, with each chain 
containing a variable region and one or 
more constant region (Fig. 3). The paired variable regions of the two Fab fragments serve as the part 
of the immunoglobulin responsible for antigen recognition and confer antigen specificity. The Fc 
 
Figure 3: Structure of the immunoglobulin molecule. The 
immunoglobulin molecule is composed two Fab fragments 
and the Fc fragment, consisting of two heavy (H) chains 
(purple) and two light (L) chains (blue), with each chain 
containing a variable (V) region and one or more constant (C) 
regions. The two Fab fragments contain a complete L chain 
and the V and first C region of one H chain (CH1). The Fc 
fragment is connected to the Fab fragments by a spacer 
hinge region between CH1 and CH2. 
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fragment is the determinant of the immunoglobulin isotype and subclass [69, 70]. There are five major 
immunoglobulin classes in humans and rodents, namely IgM, IgD, IgA, IgE, and IgG, the latter being the 
most abundant [71]. Immature B cells express IgM and IgD on their surface as they leave the BM and 
enter the blood and lymphatic circulations. In the absence of antigen, immature B cells survive only 
for a few weeks outside the BM. In response to antigen and cytokines, the immunoglobulins can 
undergo isotype switching to IgG, IgA or IgE. The isotypes differ in size, complement fixation and Fc 
receptor (FcR) binding, and different heavy chain structures results in different effector functions [69, 
72]. 
The isotype CSR is an irreversible reaction, by which deletional DNA recombinations on chromosome 
14 in humans [73] cause immunoglobulin class switch [32, 71]. Cocktails of cytokine signals or other 
extracellular influences variably initiate gene transcription [69, 73]. The cytokines IL-4 [74, 75], tumor 
growth factor (TGF)β [76, 77], and IFNɣ [78-80], as well as signals through CD40 from T cells [81] and 
crosslinking of surface immunoglobulins [80] regulate the CSR specificity. In addition, SHM takes place 
on the immunoglobulin molecules to ensure antibody diversity after exposure to antigen and by similar 
recombination mechanism as CSR [34]. In the case of SHM, point mutations occur in the genes 
encoding the V region responsible for antigen specificity as opposed to the C region in CSR. Such point 
mutations strengthen binding to antigen by affinity maturation of the antibody repertoire [34, 69]. B 
cells express the enzyme activation-induced cytidine deaminase (AID) that is required for both SHM 
and CSR, and only limited affinity maturation and immunoglobulin class switch takes place in the 
absence of AID [34, 41, 82]. Interestingly, both SHM and CSR have been shown to occur without GCs 
and independently of one another [31, 53]. Such distinct recruitment of AID to sites of CSR or SHM 
suggests that separate factors might be used by the two processes for AID recruitment, however, these 
factors remain unknown [34]. 
IgM antibodies are expressed early in B-cell development and undergo none or little SHM in response 
to antigen. These low-affinity antibodies are called natural antibodies and can bind invading pathogens 
upon entry [83]. IgD is expressed on surface of B cells as they leave the BM, and most IgD expressing 
cells also express IgM. Very low levels of circulating IgD is found in serum and IgD has a very short half-
life [69]. Functions of both membrane-bound and circulating IgD are unclear and poorly understood, 
but a role of membrane-bound IgD in regulating B-cell fate at specific developmental stages through 
changes in activation status have been proposed [84]. CSR brings about isotype switch of the 
antibodies to IgG, IgA or IgE. On mucosal surfaces and in saliva and breast milk, IgA is the most 
abundant antibody. It provides crucial protection from toxins, viruses, and bacteria by neutralization 
and by preventing such agents from attaching to mucosal surfaces. In humans, there are two 
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subclasses of IgA, IgA1 and IgA2, differing mainly in the structure of their hinge region [69]. IgE plays a 
role in responses to parasitic worms and is associated with type-I hypersensitivity or allergic reactions. 
IgE is the least abundant isotype in serum, has a short half-life, but is a potent immunoglobulin, binding 
with high affinity to FcϵRI on mast cells, basophils, eosinophils, and Langerhans cells. The potency of 
IgE is further increased when circulating IgE upregulates the expression of FcϵR. In addition, IgE binds 
FcϵRII (CD23) with low affinity [69]. 
IgG is the predominant immunoglobulin isotype found in the body and has the longest serum half-life. 
Four IgG subclasses have been identified based on structural and functional differences, IgG1, IgG2, 
IgG3 and IgG4 in humans and IgG1, IgG2a, IgG2b and IgG3 in mice [71]. A few inbred mouse strains, 
e.g. C57BL/6, also have an IgG2c gene [85, 86]. Murine immune responses usually involve all IgG 
subclasses and their proportion varies depending on the amount and type of antigen as well as co-
stimulatory signals, which again results in distinct cytokine environments [87]. IgG antibodies can 
neutralize toxins and opsonize pathogens in part through activation of the complement cascade. The 
Fc fragment on IgG antibodies can bind and activate C1q to initiate complement-dependent 
cytotoxicity. Deposition of C3b further opsonizes the target, and formation of the membrane attack 
complex, C5-C9, causes disruption of the targeted cell membrane. Different IgG subclasses affect the 
downstream events of the complement cascade differently [69, 72, 88]. A key effector function for IgG 
antibodies is antibody-dependent cellular cytotoxicity (ADCC), in which pathogens which were 
recognized and bound by an antibody, bind to FcRs on natural killer (NK) cells, monocytes, 
macrophages, DCs, and granulocytes, which again destroy the antibody-pathogen complex through 
release of cytotoxic granules [69]. In addition to activating ADCC, FcR binding leads to IgG recycling, 
phagocytosis, cell differentiation, migration, and degranulation or secretion of biologically active 
molecules [89].  
Mouse myeloid cells, NK cells, and B cells express ten FcRs, six of which bind IgG, and their expression 
is regulated by cytokines. FcRs are characterized as low-affinity receptors, binding antibodies in an 
immune complex, or high-affinity receptors, that also bind monomeric antibodies. High-affinity IgG-
binding FcRs are FcɣRI for IgG2a, FcɣRIV for IgG2a and IgG2b and FcRn for all IgG subclasses [89]. Early 
in the immune response, when T-cell help may be limited, IFN-ɣ and TGF-β facilitate class switch to 
complement-binding IgG3 [80, 90] and IgG2b [77], respectively, that ensures early recruitment of FcɣR-
mediated effector functions [89]. Class switch to IgG2a occurs later, is supported by IFN-ɣ [91], and is 
associated with stronger FcɣR-mediated ADCC activity than IgG2b [92-94]. Class switching to IgG1, and 
later to IgE is promoted by IL-4 [95, 96]. IgG1 can neutralize toxins and viruses by steric hindrance, but 
only engages with the inhibitory FcɣRIIb to limit IgG-driven inflammatory processes. Importantly, IgG 
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subclasses are co-expressed and exhibit combined effector functions [87]. Human and murine FcR 
effector functions differ and are not fully corresponding to each other [89]. 
Toll-like receptors and their signaling 
Toll-like receptors (TLRs) play an important role in innate and adaptive immunity by recognizing 
specific molecular components on microbes, so called pathogen-associated molecular patterns 
(PAMPs) [97]. Pathogens express various ligands that are recognized by different TLRs or other pattern 
recognition receptors (PRRs) such as RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), C-type 
lectin receptors (CLRs), and cytosolic dsDNA sensors (CDSs) [98-100]. TLR activation induces 
inflammatory responses in APCs and facilitates antigen-specific adaptive immunity [101]. TLRs are 
involved in different phases of the immune response, starting with pathogen recognition by APCs that 
causes expression of pro-inflammatory cytokines and chemokines, which again regulate DC homing to 
lymph nodes where antigen presentation and activation of adaptive immunity takes place [102]. 
Coupled with the fact that antigens alone induce weak antibody responses unless they are haptenated 
or aggregated [103], makes TLR ligands attractive as adjuvants in vaccines [100, 104]. 
The first receptor to be identified was TLR4 in 1997 [105] and to date, ten human and 12 mouse TLRs 
are known [98]. Most TLRs are located on the cell plasma membrane, however, TLR3, TLR7, TLR8, and 
TLR9 localize to endosomes [98, 106-108]. Activation of TLRs leads to recruitment of cytosolic adaptor 
proteins of which five have been identified: MyD88, MAL, TRIF, TRAM, and SARM [109]. These adaptors 
are linked to the downstream signaling pathways, which are dependent on either MyD88 or TRIF. TLR 
signaling leads predominantly to production of pro-inflammatory cytokines [98]. All TLRs, except TLR3 
[110, 111], require MyD88, which subsequently induces NF-κB transcription and cytokine production 
[112]. Both TLR3 and TLR4 can utilize the TRIF signaling pathway, which can mediate activation of both 
NF-κB and interferon regulatory factor 3 (IRF3), leading to production of type-I IFNs [111]. Activation 
of TLR4 is unique in that it can use both MyD88- and TRIF to propagate immune signaling. However, it 
is currently unclear what dictates whether TLR4 utilizes the MyD88 or TRIF signaling pathway, and the 
pathways may play different roles in regulating TLR4-induced immune responses in lymphoid and 
myeloid cells [113]. Simultaneous activation of TLRs and the BCRs on B cells can initiate CSR of 
antibodies as it causes synergistic activation of canonical and non-canonical NF-κB pathways leading 
to AID expression. In TD responses, CD40 signaling from T cells similarly triggers NF-κB activation and 
AID expression, but through different signal transducers. These findings imply that TI and TD CSR 
require the same set of transcription factors that are critical for AID induction [114]. 
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Vaccination 
Prophylactic vaccination 
Vaccination has made a major impact on global population health and successful vaccination is the 
most effective measure to prevent disease against future pathogens [115-118]. Not only have diseases 
been controlled or even eradicated, vaccines have huge socio-economic benefits and added values 
such as reduction in antibiotic resistance, extended life expectancy by protecting from other diseases, 
safer traveling, empowerment of women, decreased infant mortality, reduced health-care cost and 
overall an economic growth [117].  
Prophylactic vaccines can be classified into two groups. The first group is comprised of live attenuated 
pathogens activating protective immunity similar to that seen in people who survive natural infection 
[119]. These vaccines protect against acute infections caused by invariant pathogens, induce potent 
immune responses, and have shown good efficacy with long-lived immunity. In fact, the smallpox and 
yellow fever vaccines confer lifelong memory and serve as gold standards [120]. The second group of 
vaccines includes subunit vaccines, inactivated toxins, carbohydrate vaccines and conjugate vaccines 
that usually contain adjuvants to enhance immune responses [119].  
Current vaccines protect exclusively against diseases by eliciting antibody responses capable of 
reducing replication of microbes or neutralizing microbial toxins [121-123]. Efficacy of vaccination 
depends on the magnitude, quality and persistence of the antibodies induced. The magnitude of 
antibody responses is particularly important for vaccines against diphtheria, tetanus, Lyme disease, 
hepatitis A, polio, rabies, yellow fever, as well as N. meningitidis, and S. pneumoniae [119]. The efficacy 
of several other vaccines depend more on the quality of the antibody response, such as neutralizing 
capacity, affinity and their effector functions, which again is a result of the antibody isotype and 
subclass [122]. The appropriate utilization of adjuvants can help production of memory B cells and 
long-lived PCs, thereby shaping the antibody responses [121-123].  
Despite remarkable successes in vaccine development, drawbacks such as production difficulties and 
safety issues, especially in immune deficient patients, has led to research and development of 
alternative vaccines [124]. In addition, there is a lack of effective vaccines against important human 
diseases. Highly variable pathogens and those causing persistent and latent infections such as HIV, 
hepatitis C virus and tuberculosis have been the subject of extensive research without a successful 
vaccine [125-127]. Development of effective vaccines has proven difficult where acute infections do 
not necessarily result in long-term memory and protection from reinfections, as for respiratory 
syncytial virus (RSV), malaria, and tuberculosis [128]. Recently, vaccines exploiting virus-like particles 
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(VLPs) have been marketed against human papillomavirus, Hepatitis B, and malaria, and other VLP 
vaccines are in clinical trials [124]. 
Allergen immunotherapy (AIT) 
Globally, 400 million people suffer from allergic rhinitis, 300 million from asthma and nearly 250 million 
from food allergies, and the prevalence and impact of allergies are on the rise [129-131]. Traditionally, 
allergies have been associated with industrial countries, yet, reports indicate that in Asia-Pacific region 
and in tropical South-East Asia prevalence of allergic disease has reached the highest level in 50 years 
[132]. Allergen immunotherapy (AIT) is the only disease-modifying treatment with long-term effects 
[133]. AIT has been shown to reduce allergy symptoms and improve quality-of-life [134], as well as to 
reduce the risk of multiple sensitization [135], reduce rescue medication [136], and it may reduce 
progression to asthma [137, 138] and food allergy [139, 140].  
Currently, AIT is mainly applied subcutaneously (SCIT) and sublingually (SLIT) for treatment of allergies 
to grass and tree pollens, pet dander, house dust mites, and venom [133, 141-143]. Both treatments 
consist of a dose build up, followed by 3-5 year maintenance phase. SCIT is administered by injections 
every 4 to 8 weeks [144], while SLIT is administered in a solution or a tablet with daily dosing regimens 
[133, 136, 145]. SCIT has “proven value”, but is also associated with a 0.1-0.2% risk of severe adverse 
reactions [146]. SLIT was introduced as a safe and effective alternative to SCIT in the 1990ies. Oral 
immunotherapy (OIT) of IgE-mediated food allergy has been shown to desensitize against peanut 
[147], egg [148], and cow’s milk allergies [149]. However, successful long-term tolerance is induced in 
minority of patients and adverse events are common during OIT, therefore competent personnel 
trained in managing anaphylaxis should administer treatment [150-152].  
Important goals of current AIT research is to increase safety and to enhance efficacy [132, 133, 153]. 
Further emerging approaches include optimizing delivery by direct administration to immune 
compartments to reinforce immune responses [141, 144]. Only one in 107 T and B cells can recognize 
a specific antigen due to diverse repertoire of receptors on these cells. For this reason, antigens must 
be presented to millions of cells to elicit a response [12]. Since immune response requires the 
interaction of DCs, T cells and B cells, antigen delivery to sites where these cells are present in high 
numbers would facilitate reactions [12, 144]. Langerhans cells are APCs present in high numbers in the 
epidermis. For this reason, epicutaneous or transcutaneous AIT was introduced as a treatment option 
for allergies [154]. High numbers of immune cells are also present in lymph nodes for which reason 
intralymphatic immunotherapy (ILIT) is another attractive treatment option in allergy [12, 155]. The 
vaccine is injected directly into a subcutaneous lymph node under ultrasound guidance [12] and all of 
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the allergen is delivered to the lymph nodes [155]. Hence, the immunogenicity of a peptide-based ILIT 
vaccine enhances as much as million-fold compared to a SCIT vaccine [156]. The targeted delivery 
allows the use of lower allergen doses and fewer injections, which again should lower the incidence of 
local and systemic allergic side effects [144].  
Allergic sensitization depends on TH2 differentiation of allergen-specific CD4 T cells, which through 
release of cytokines such as IL-4 and IL-13 facilitate IgE class switching as well as development of 
memory T- and B-cell responses. It is the binding of allergen-specific IgE to FcεRI on mast cells and 
basophils which then leads to allergic sensitization [157]. Upon sensitization and memory induction, 
IgE-mediated elicitation of allergic reactions typically occurs in two immunological phases. The 
immediate phase takes place when IgE bound to FcεRI on mast cells and basophils is cross linked by 
allergens and is characterized by degranulation of the mast cells and basophils with release of bioactive 
amines, lipids mediators, chemokines and cytokines [141]. The late phase is characterized by tissue 
inflammation due to infiltrating T cells, and tissue injury which further trigger infiltration of 
granulocytes [158].  
AIT can lead to long-term cease of allergy symptoms by the induction of allergen-specific immune 
tolerance, which can be considered as a series of changes in T- and B-cell responses as well as in the 
activation thresholds for mast cells and basophils [158]. Regulatory T cells (TREGs) are induced early in 
AIT and play a pivotal role in inducing and maintaining immune tolerance by production of IL-10 and 
TGFβ that suppress inflammation by multiple mechanisms [159, 160]: (i) the suppression of mast cells, 
basophils and eosinophils [161, 162]; (ii) the suppression of APCs that support the generation of TH1 
and TH2 cells [158]; (iii) the direct suppression of TH1 and TH2 cells [163]; (iv) the suppression of 
allergen-specific IgE; (v) the induction of IgG1 and IgG4 [164]; (vi) the indirect inhibition of TH2-
associated mucus production and activation of endothelial cells; and (vii), the TH1-associated activation 
of epithelial cells and apoptosis [158]. 
During AIT, serum IgE increases transiently before it gradually decreases over months or years of 
treatment [165]. However, seasonal increases in IgE are weakened and serum IgE levels do not 
correlate directly with clinical improvement [166]. IgG antibodies, particularly IgG4, protect from 
allergic responses by binding allergen and either inhibit its binding to IgE on effector cells by direct 
competition, or block degranulation through the inhibitory FcɣRIIB receptor [167, 168]. In addition, 
IgG4 antibodies can prevent binding of IgE-allergen complexes to FcεRII (CD23) on B cells, thereby 
reducing presentation of allergen to T cells [169, 170]. The blocking activity of IgG antibodies depends 
on their affinity for the allergen rather than quantity of antibodies [132, 141]. Knowledge of the 
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underlying mechanisms of AIT allows for development of biomarkers to predict efficacy and side 
effects and to monitor clinical response. Recent recommendations suggest that the efficacy of 
treatment correlates with the extent to which IgE can be hindered from binding to the allergen and 
causing an allergic response [166].  
Major concerns with AIT are the incidence of adverse events as well as long duration of treatment 
challenging patient compliance [133, 144, 152]. Strategies aimed at improving therapy rely on 
modifying the allergen structure in such a way that reduces its ability to cross-link IgE, while 
maintaining the ability to target allergen-specific T cells and induce immune tolerance [132]. Methods 
changing the allergen structure include use of allergen fragments including peptides [171, 172], 
allergen multimers [173] and engineered recombinant hypoallergenic molecules [174], all of which 
would simplify standardization of allergen production and AIT safety as compared with allergen 
extracts [175]. Firstly, peptide immunotherapy uses short soluble synthetic peptides containing the 
immunodominant T-cell epitopes of major allergen proteins, but lack the length and three-dimensional 
structure to cross-link IgE. The use of synthetic peptides in AIT may induce antigen-specific hypo 
responsiveness, a shift from TH2 to TH1, induction of TREGs and clonal deletion through exhaustion [176, 
177]. Secondly, contiguous overlapping peptides fail to form the three-dimensional structure causing 
IgE binding and allergic reactions. Such antigens allow faster dose escalation and administration of 
higher allergen doses [173, 178]. Finally, recombinant allergens have great potential for increasing the 
safety of AIT as they can be genetically modified to reduce allergenicity and IgE binding [179]. Such an 
approach may ultimately allow individually tailor-made immunotherapy without the risk of novel 
sensitizations to irrelevant allergens present in extracts.  
Immunotherapy for CD8 T-cell activation and cytotoxicity 
With increased understanding of the immune system, vaccine researchers have also acknowledged the 
potential of cancer immunotherapy or therapeutic vaccination against intracellular pathogens [180, 
181]. Such therapy aim at the induction of cytotoxic CD8 T cells (CTLs), which recognize antigens and 
oncogenes presented on MHC class I molecules on infected cells and tumor cells, respectively. The 
CTLs then kill through perforin- and granzyme-mediated mechanisms. The triggering of CTL responses 
requires that vaccine antigens are targeted to the cytosol of APCs, especially DCs, for correct 
processing in the proteasomes and access to the MHC class I pathway of antigen presentation [182]. 
In parallel, CD4 T helper cells are activated through MHC class II antigen presentation and provide 
important helper and co-stimulatory signals to the DC for efficient CTL activation [183]. The efficiency 
of CTL induction also depends on frequency and duration of antigen presentation making it important 
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for high doses of vaccine antigen to reach the cytosol of DCs. The caveat is that soluble peptide and 
protein antigens only poorly reach cytosol and the MHC I antigen presentation pathway [184]. 
Consequently, soluble vaccines induce relatively weak CD8 T-cell responses as they are rather 
processed through the MHC II pathway. Focus of research has therefore been directed toward the 
development of potent adjuvants providing cytosolic delivery and appropriate co-stimulatory signals 
[156]. 
Adjuvants 
Proteins and peptides are known to have poor immunogenicity, largely due to inefficient recognition 
and uptake by APCs and the inability to trigger APC activation, e.g. through PRRs. Therefore, vaccine 
antigens are typically combined with adjuvants or delivery systems intended to enhance the 
magnitude and modulate the quality of the immune responses [122, 185-187]. An ideal adjuvant is 
safe, well tolerated, easy to scale up and manufacture, with reasonable shelf life, compatible with 
antigen and economically feasible [188]. Today, only few adjuvants are licensed for use in humans, 
namely aluminum salts (alum), adjuvant system 04 (AS04), VLPs, virosomes, and oil-in-water emulsions 
such as MF59 and AS03 [185, 189, 190]. Adjuvants can be particulate like alum, emulsions, liposomes, 
virosomes, and microparticles or combinational where particulate adjuvants have been combined with 
immune potentiators such as TLR ligands. AS04 is an example of such and adjuvant and is comprised 
of alum and the TLR4 ligand monophosphoryl lipid A (MPLA) [185]. Indeed, TLR ligands are an emerging 
class of adjuvants that in general stimulate APCs to prime especially TH1 responses.  
The lack of available adjuvants reflects a knowledge gap in the mechanisms of adjuvant action and 
potential toxic effects [122]. Currently, many types of adjuvants are being developed. One issue in 
adjuvant design is to control how the adjuvants stimulate specific immune responses required for 
protection or effective therapy, such as the stimulation of specific helper T cell subset, cytotoxic T cells 
or long-term memory T cells or B cells. Addressing this issue requires an understanding of how 
successful adjuvants mediate their immunogenicity [122]. 
Alum based adjuvants, are the oldest and most frequently used adjuvants in licensed vaccines [186]. 
Alum provides an antigen depot at the site of injection and facilitates uptake into APCs due to its 
particulate nature [191]. Furthermore, recent research has also shown that alum  induces cell death, 
causing release of cellular DNA that is recognized as danger-associated molecular pattern (DAMP) by 
APCs [191, 192] and activation of the NLPR3 inflammasome [193]. Such an inflammatory response 
recruits further APCs to the site [194], thereby amplifying antigen uptake, presentation, and adaptive 
immune response [195]. Alum promotes a strong TH2 response independently of TLR signaling [192, 
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196], and exerts a direct effect on IL-4 -producing myeloid cells essential for priming, clonal expansion, 
and optimal antibody production by B cells [197]. Despite the success of alum as adjuvant in 
prophylactic vaccines and in AIT, it has limited use in vaccines against intracellular pathogens or 
pathogens requiring a strong cellular immune response [186]. To overcome the limitations of alum, it 
has been co-delivered with other adjuvants such as MPLA in AS04, by such a combination, both TH1 
and TH2 responses can be stimulated [198]. Alum is a commonly used adjuvant in AIT vaccines and 
despite its efficacy and safety, novel adjuvants are needed to overcome current problems with 
conventional immunotherapy. Replacement of alum with TLR ligand such as MPLA or CpG promotes 
TH1 polarization and may reduce the number of injections needed in AIT [141, 144, 199]. 
Liposomes in antigen delivery 
Liposomes are spherical particles of approximately 25-1000 nm containing one or more bilayer of 
phospholipids in aqueous solutions [184] and typically regarded as immunologically inert [200]. 
Liposomes can be effective carriers of antigens, which can be either encapsulated in the aqueous core, 
embedded in the lipid membrane, or absorbed on or conjugated to the liposomal surface [184]. The 
surface charge, rigidity, and size of the liposomes, as well as the density of antigens on the liposomal 
surface, influence the overall immune responses induced with antigen-loaded liposomes [184, 201]. 
Liposomal particles smaller than 200 nm efficiently drain through lymphatic vessels to the lymph nodes 
[12, 155] and thereby resemble most live attenuated vaccines [202]. While pathogens naturally display 
multiple PAMPs on the surface, liposomes can be engineered to carry also immune stimulatory 
molecules such as TLR ligands on the liposomal surface [122, 203]. Liposomes have been shown to be 
able to deliver antigens to the cytosol, leading to MHC I presentation and the induction of CTL 
responses [201]. In pre-clinical testing, multiple different liposomal vaccines have effectively 
stimulated antibody production sufficient to hinder infection, or induced potent antigen-specific CTL 
responses in cancer immunotherapy [204-206]. In addition, many vaccines have been shown to be safe 
and induce immune responses in clinical trials [207, 208]. Finally, a liposomal based vaccine against 
malaria (Mosquirix®) has been marketed [209] and virosomes, made of liposomes, are one of few 
licensed adjuvants and are used in hepatitis A (Epaxal®) and influenza (Inflexal®) vaccines [189]. 
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Aims and outline of the thesis 
The main objectives of the research presented in this PhD thesis were: 
 to design short ovalbumin peptides for formulation into liposomal vaccines for T-cell 
independent stimulation of antibody responses, 
 to study the mechanism by which T-cell independent liposomal vaccines stimulate antibody 
responses in mice,  
 to investigate the role of T cells in allergen immunotherapy,  
 to study the importance of dosing intervals in intralymphatic allergen immunotherapy, and  
 to test the potential effect of liposomes to improve delivery of photosensitizer and antigen to 
the MHC I pathway for stimulation of CD8 T-cell responses. 
 
The research in chapter 2 focuses on the development, testing, and immunological characterization of 
liposomal vaccines loaded with ovalbumin (OVA) peptides and monophosphoryl lipid A (MPLA). The 
goal was to achieve one or several vaccines that due to the densely arranged peptides and MPLA 
adjuvant on the liposomal surface could activate B-cell responses directly and independent on T cells. 
It is generally recognized that antibody responses stimulated in the absence of T-cell help show limited 
isotype class switch and affinity maturation. B cells activated in the absence of T-cell help also lack a 
memory function in response to secondary antigen encounter. Functional B-cell memory has only been 
reported with polysaccharide antigens. The aim of this study was to investigate the nature of antibody 
responses in the absence of T cells, e.g. to elaborate on the required cellular signaling and to test the 
antibody function in vivo. 
The focus of AIT research aims at improving therapeutic efficacy and safety. It is well documented that 
AIT induces both B- and T-cell responses, but their relative importance in AIT efficacy is frequently 
subject to discussions and research, for instance using murine models of T-cell depletion or adoptive 
transfers of B cells, T cells or antibodies in mice. The goal of chapter 3 was to study the role of T cells 
in allergen immunotherapy (AIT). The above-described OVA-peptide- and MPLA-loaded liposomes 
were used as a tool for T-cell independent AIT, while OVA protein adsorbed on the adjuvant aluminum 
hydroxide (alum) was used as T-cell dependent control vaccine in AIT. As T-cell independent antibody 
responses arise fast and IgG class switch was feasible (chapter 2), it was of interest to explore the 
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potential of a T-cell independent allergy vaccine in AIT. The investigations were performed using an in 
vivo model of allergic anaphylaxis. 
There are conflicting reports on the importance of AIT dosing intervals on the immunological and 
clinical effects in AIT after intralymphatic administration, so-called ILIT. One parameter that was 
suggested to cause conflicting results was the time interval by which the ILIT was administered. In 
chapter 4, mice were sensitized with OVA and treated by ILIT using treatment intervals ranging from 
one to four weeks. The therapeutic efficacy was studied using the mouse model of allergic anaphylaxis. 
A limitation of current vaccines and a major challenge in vaccinology is the stimulation of T-cell 
responses, especially cytotoxic CD8 T-cell responses. The poor CD8 T-cell responses are in part due to 
non-efficient delivery of antigen to the cytosol of antigen-presenting cells (APCs) and subsequent 
processing in the MHC class I-restricted pathway of antigen presentation. In chapter 5, liposomes were 
utilized to facilitate delivery of an antigen and a photosensitizer to APCs in vivo, after intradermal 
administration to mice. The experimental goals were to improve APC phagocytosis and CD8 T-cell 
stimulation, where the photosensitizer enabled phagosomal disruption and MHC class I antigen 
processing upon light activation. Photosensitizer and OVA were separately formulated in liposomes, 
and antigen-specific T- and B-cell responses were assessed in vivo and in vitro using various 
immunological methods. 
Finally, in chapter 6, the overall results and conclusions of this PhD thesis are discussed. Furthermore, 
the potential application of T-cell independent vaccines is discussed, and suggestions are given for 
further research in the field of my PhD project. 
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Abstract 
T lymphocytes are generally required for B-cell activation and immunoglobulin class switching in 
response to peptide antigens. In the absence of T cells, limited IgG class switch takes place, germinal 
centers are short-lived, and the B cells lack memory. We show that immunization of mice with 
liposomes containing 15mer peptides and monophosphoryl lipid A elicits T-cell independent (TI) IgG 
class switch within three days as well as germinal center formation. The long-lived antibody responses 
were strictly dependent on MyD88 signaling and partly dependent on BTK signal transmission, thereby 
showing characteristics of both TI type 1 and TI type 2 antibody responses. IgG responses of all 
subclasses could be boosted months after primary immunization, and the biological function of the 
secreted antibodies was demonstrated in murine models of allergic anaphylaxis and of bacterial 
infection. This is the first study that demonstrates T-cell independent endogenous B-cell memory and 
recall responses in vivo using a peptide antigen. The stimulation of these immune responses required 
a correct and dense assembly and administration of peptide and adjuvant on the surface of liposomes. 
In the future, TI vaccines may prove beneficial in pathological conditions were T-cell immunity is 
compromised through disease or medicines or when rapid and antibody-mediated immune protection 
is needed.   
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Introduction  
Activation of B cells and subsequent antibody production require help of CD4 T-helper (TH) cells when 
antigen is a protein [1]. In contrast, polysaccharides and lipopolysaccharides (LPS) can activate B cells 
without the help of TH cells [9]. The first step in stimulating T-cell dependent (TD) and independent 
(TI) antibody responses is that antigen binds B-cell receptors (BCRs). TD antigens are internalized, 
processed and presented to antigen-specific T cells on MHC class II molecules [210]. This process takes 
place in secondary lymphoid organs, where activated T cells provide stimulatory signals to B cells, 
which differentiate into short-lived extrafollicular plasma cells, early memory cells, or germinal center 
(GC) B cells [9, 35, 38, 211, 212]. In the GCs, IgM on B-cell surfaces undergo irreversible 
immunoglobulin class switch and affinity maturation [32], and the B cells differentiate into antibody-
secreting plasma cells or long-lasting memory B cells [35, 38, 47, 213]. In general, TI antigens do not 
induce GC formation or memory B cells [52]. 
Type-1 TI (TI-1) antigens may activate B cells through signaling via Toll-like receptors (TLR) that 
recognize microbial ligands or synthetic ligands such as poly(I:C) [9]. In contrast, TI-2 antigens are 
typically repetitive, e.g. bacterial capsular polysaccharides. Such antigens extensively cross-link BCRs 
and deliver prolonged and persistent signals to the B cell, signals that are transmitted through the 
cytoplasmic enzyme Bruton's tyrosine kinase (BTK) [28, 29]. While IgG antibody responses to TD 
antigens are slow, TI antigens elicit fast, potent and long-lived extra-follicular antibody responses that 
can be critical to control blood-borne infections [4, 6, 7, 31, 51, 52]. 
Immunization with the TI-2 antigen NP-Ficoll have been shown to form GCs in transgenic mouse 
models with high numbers of high-affinity antigen-specific B cells [52, 53]. In C57BL/6 mice and in T-
cell deficient mice, GCs also formed in response to NP-Ficoll [51], however, these GCs were short-lived, 
with limited affinity maturation and class switch [27, 51-53]. TI-associated GCs require extensive cross-
linking of BCRs and are independent of CD40L or CD28 signaling [52]. In TD-associated GCs, 
proliferating B cells, known as centroblasts, undergo somatic hypermutation in the dark zone of the 
GCs. The centroblasts exit the cell cycle as smaller, non-dividing centrocytes that move to the light 
zone, where mixing with follicular dendritic cells (FDCs), follicular TH (TFH) cells, and macrophages [25, 
32, 35, 40]. This interaction results in selection and survival of high-affinity centrocytes and provides 
signals for differentiation of B cells to long-lived plasma cells and memory B cells [42-44, 214].  
A unique type of extra-follicular memory B cells has been identified in response to both TI-1 and TI-2 
antigens [8, 10, 61]. However, recall responses to these TI antigens were only obtained in murine 
models of adoptive B-cell transfer [10, 56, 58-61]. The secondary activation of TI-memory B cells was 
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tightly regulated by antigen-specific antibodies, potentially as a self-tolerance mechanism to avoid 
antibody over-production [8, 59, 61]. However, protection upon secondary infection can be provided 
by long-lived bone marrow plasma cells independent of T cells [62] 
In the present study, immunization with short peptide antigens and a TLR4 ligand densely arranged on 
the surface of small unilamellar liposomes activated B cells directly and independent of T cells, with 
generation of long-lived and class-switched antibodies, B-cell memory, and formation of GCs. The 
antibody responses showed characteristics of both TI-1 type reactions a TI-2 type reactions, being 
dependent on MyD88 and in part also on BTK signaling. To our knowledge, this is the first study that 
demonstrates endogenous and T-cell independent B-cell recall responses in vivo using peptide 
antigens. 
 
Methods 
Mice  
BALB/c (BALB/cOlaHsd, H-2d), C57BL/6 (C57BL/6JOlaHsd, H-2b), and athymic nude (Hsd:AthymicNude-
Fox1) mice were purchased from Envigo (Horst, the Netherlands). CBA (CBA/J, Pde6brd1), BTK- 
(CBA/CaHN-Btkxid/J), and TRIF-deficient (C57BL/6J-Ticam1Lps2/J) mice were purchased from Jackson 
Laboratories (Bar Harbor, Maine, USA). TLR4- (B6-TLR4tm1Aki), MyD88- (B6-MyD88tm1Aki), MHC class II- 
(B6-I-Aatm1Blt), and TCR-deficient (B6.129P2-Tcrbtm1Mom Tcrdtm1Mom) mice were from the Swiss 
immunological mouse repository (SWIMMR). Mice were kept and bred under SPF conditions at the 
animal facility of the Biologisches Zentrallabor, University Hospital Zurich. Only female mice were used, 
and all procedures were approved by the animal Research Ethics Board and the Zurich cantonal 
veterinary office (license ZH 98/2014).  
Preparation of peptide liposomes 
Liposomes were prepared from dimyristoyl phosphatidyl choline (DMPC), dimyristoyl phosphatidyl 
glycerol (DMPG), cholesterol (Solvay, Brussels, Belgium), and monophosphoryl lipid A (MPLA; Avanti 
Polar Lipids, Alabaster, USA) as previously described [215], and as illustrated in Figure 1A. Chicken 
ovalbumin (OVA) was used as antigen, whereby short peptides thereof were designed for formulation 
in the liposomes. The peptide design took into consideration immunological and physicochemical 
characteristics (Table 1), thereby avoiding known T-cell binding and IgE-binding epitopes, but including 
IgG-binding epitopes [216-223]. The chosen OVA-derived sequences were synthesized and flanked 
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with two palmitoylated lysines (Lys) on each terminal side of the peptide (PolyPeptide Laboratories, 
Strasbourg, France). The liposomes were loaded with 101-648 µg/ml peptide and 56-169 µg/ml MPLA. 
Table 1: Peptides from ovalbumin (OVA) formulated in liposomes. Characteristics of short OVA peptides 
synthesized and tested for T-cell independent immunization. Exclusion criteria for the peptide selection were 
known T-cell or IgE-binding epitopes while peptides with known IgG-binding epitopes were included [216-223]. 
Minor amino acid mutations were created to assure peptide stability and solubility. The peptides were 
synthesized and flanked with two palmitoylated amino acids (Lys) on both the N- and C-terminal side. The fatty 
acid-derived palmitoyl group facilitated anchoring of the peptide in the bilayer of liposomes [224]. The N-terminal 
amino group of all the peptides was kept free while the C-terminal carboxylic group was capped as amide. 
Code Amino acids Sequence 
OVA aa 
Length 
(aa) 
Aliphatic 
Index1 
Instability 
Index2 
OVA1 H-Lys(Pal)-Lys(Pal)-FKELKVHHANENIFY-Lys(Pal)-Lys(Pal)-NH2 15-29 15+4 61.58 32.91 
OVA2 H- Lys (Pal)- Lys (Pal)-RFDKLPGFGDSIEAQ-Lys(Pal)-Lys(Pal)-NH2 58-72 15+4 46.32 67.59 
OVA3 H-Lys(Pal)-Lys(Pal)-TKPNDVYSFSLASRY3-Lys(Pal)-Lys(Pal)-NH2 91-105 15+4 41.05 7.71 
OVA4 H-Lys(Pal)-Lys(Pal)-RNVLQPSSVDSQTA-Lys(Pal)-Lys(Pal)-NH2 158-171 14+4 59.44 97.67 
OVA5 H-Lys(Pal)-Lys(Pal)-RNVLQPSSVDSQTAMVLV-Lys(Pal)-Lys(Pal)-NH2 158-175 18+4 92.73 80.42 
OVA6 H-Lys(Pal)-Lys(Pal)-VFKGLWEKAFKDEDTQA-Lys(Pal)-Lys(Pal)-NH2 179-195 17+4 41.9 -3.18 
1 The aliphatic index is regarded as a positive factor for solubility of proteins [225]. 
2 The instability index has been shown to inversely correlate with in vivo half-life [225]. 
3 Original sequence was TKPNDVYSFSLASRLY 
 
Immunization of mice 
Typically, groups of five mice were immunized subcutaneously (s.c.) in the scruff of the neck with OVA-
derived peptide- and MPLA-loaded liposomes or OVA on alum. A single dose ranged from 2-36 µg 
peptide and 1.3-25.6 µg MPLA, and the liposomes were diluted in phosphate-buffer saline (PBS) prior 
to injection. T-cell dependent control vaccines were made using full Grade V OVA protein from Sigma-
Aldrich (Buchs, Switzerland) mixed with aluminum hydroxide (Alum; Alhydrogel 2%) from Brenntag 
Biosector (Frederikssund, Denmark). OVA was allowed to absorb on alum for one hour at room 
temperature, before dilution in PBS. The OVA doses ranged from 10 to 100 µg OVA and the alum dose 
was kept at 1 mg. When indicated, the immunization was repeated, and mice were bled from the tail 
vein for later antibody analysis by ELISA. 
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Measurement of OVA-specific antibody responses by ELISA 
OVA-specific IgM, IgG1, IgG2a, IgG2b, IgG3, and IgE antibody responses were determined by a 
sandwich ELISA [226]. Briefly, the plates were coated with 50 µl 4 µg/ml OVA for IgM and IgG subclass 
detection and with 3 µg/ml anti-mouse IgE (AbD Serotec, Düsseldorf, Germany) for detection of IgE. 
OVA-specific IgE was detected with an in-house biotin-conjugated OVA, while IgM and IgG subclasses 
were detected with biotin-conjugated goat anti-mouse IgM or IgG subclass-specific antibodies (Abcam, 
Cambridge, United Kingdom), respectively. All plates were developed with streptavidin-conjugated 
horseradish peroxidase (HRP) and with TMB substrate (eBioscience, San Diego, CA, now Thermo 
Fischer). Reaction was stopped with 25 µL of 2N sulphuric acid (H2SO4) and absorbance read at 450 nm 
on a BioTek Instruments plate reader (Winooski, VT). Antibody titers were defined as the highest 
dilution with absorbance two times that of sera from untreated mice, or optical density (OD) of 0.1. 
Alternatively, the OD at a given, non-saturated serum dilution was measured for IgG2b, IgG3 and IgM, 
while the serum concentration of OVA-specific antibodies was calculated against standards for IgG1, 
IgG2a (BioLegend, San Diego, CA) and IgE (AbD Serotec). 
ELISA for avidity measurements 
The avidity of serum antibodies were measured in three steps as previously described [227-229]. 
Firstly, the ELISA was optimized so that the amount of serum antibody binding the OVA-coated plate 
represented a small portion of the amount of antibody in the non-binding liquid phase. The amount 
was equivalent to a developed ELISA of OD 0.2. Secondly, each individual test serum was diluted to 
obtain the optimal antibody concentration (OD 0.2). Thirdly, the diluted sera were incubated at room 
temperature with OVA protein at a range of OVA concentrations and for two hours. The sera were 
then transferred to OVA-coated plates and the ELISA developed. The concentration of OVA needed to 
inhibit 50% of the antibodies from binding to the plate (IC50) was calculated by “log (inhibitor) vs 
response” fitting using GraphPad Prism 7.02 (GraphPad Software Inc., La Jolla, CA). Sera from individual 
mice within each treatment group was pooled to yield one sample per group. 
Germinal center analysis by immunohistochemistry, immunofluorescence and flow cytometry 
BALB/c mice were immunized intravenously (i.v.) with 10 µg peptide-loaded liposomes. As a positive 
control for germinal center (GC) formation, 10 µg Qβ virus-like particles (VLPs) was administered [230]. 
Spleens were harvested for the analysis of GCs 5, 8, 13 and 20 days after injection, and the tissues were 
snap-frozen for immunohistochemistry (IHC). The frozen sections were stained with peanut agglutinin 
(PNA) and anti-B220. Athymic nude mice were immunized in the same way, and spleens were 
harvested 3, 5, and 10 days after injection and snap-frozen for staining by immunofluorescence (IF). 
 
 
 
A novel type of peptide-induced T-cell independent B-cell responses with class switch and memory using liposomes 
 
35 
The frozen sections were stained with PNA-Dylight549, anti-B220-Dylight488 and DAPI. All stainings 
were outsourced to Sophistolab AG (Muttenz, Switzerland). 
Alternatively, spleens were harvested seven days after injection with peptide-loaded liposomes or with 
VLPs and analyzed by flow cytometry after RBC lysis, FcR blocking with anti-CD16/32 antibodies, and 
staining with fluorescently labelled anti-B220, anti-GL-7, and anti-CD38 (all eBioscience). Germinal 
center B cells were defined as positive for B220 and GL-7 and negative for CD38. Acquisition was done 
with FACSCanto (BD Bioscience, Basel, Switzerland) and analysis with FlowJo 10.0.8 (FlowJo, LLC, 
Ashland, OR). 
Analysis of systemic anaphylaxis 
BALB/c mice were immunized s.c. with 10 µg peptide-loaded liposomes or with 100 µg OVA protein on 
alum, as described above. On week 4, a booster vaccine was given. On weeks 8 and 10, all mice 
received s.c. injections of 100 µg OVA on alum in 100 µL PBS as to produce OVA-specific IgE 
sensitization. On week 14, mice were challenged by intraperitoneal (i.p.) injection of 50 µg OVA in 100 
µl PBS, and anaphylaxis was analyzed by measuring the rectal temperature before and after the 
challenge using a digital thermometer (Thermalert TH-5 with a RET-3 probe, Physitemp, Huron, NJ). 
Adoptive IgE sensitization of nude mice by serum transfer  
As IgE class switch is dependent on T cells [231], nude mice cannot be IgE sensitized. Therefore, 
athymic nude mice were adoptively transferred with serum from IgE-sensitized BALB/c mice. Twenty 
hours after serum transfer, the nude mice were challenged for induction of anaphylaxis as described 
above. One group of nude mice was immunized s.c. with 10 µg peptide-loaded liposomes 3 and 7 
weeks prior to serum transfer. The goal of this experiment was to test the functionality of TI antibodies. 
Infection of mice with Listeria monocytogenes 
To investigate if immunization with the peptide- and MPLA-loaded liposomes could control acute 
bacterial infections, BALB/c mice were immunized s.c. with 10 µg of peptide- and MPLA-loaded 
liposomes as described above. Booster immunization were given when indicated, and blood was 
collected for detection of antigen-specific antibodies. One to three weeks after the last immunization, 
the mice were infected with OVA-expressing and streptomycin-resistant Listeria monocytogenes [232], 
kindly provided by Dietmar Zehn (School of Life Sciences Weihenstephan, Technical University of 
Munich, Germany). Briefly, bacterial stocks were grown to mid log phase in brain-heart infusion (BHI) 
broth, and the bacteria quantified by measuring the OD at 600 nm. Mice received 10.000 colony-
forming units (CFU) in PBS by i.v. injection, and the bacterial burden in spleen and one liver lobe was 
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analyzed after 48 hours. Organs were collected in PBS, mashed through a 70 µm cell strainer and 
homogenates incubated with 2.5% saponin (Sigma-Aldrich) for 60 minutes at room temperature 
before serial dilutions of organ lysates were spread onto BHI agarose plates supplemented with 200 
µg/mL streptomycin. After 48 hours of incubation at 37°C, the CFU were counted and the organ 
bacterial burden calculated. 
Statistical analysis 
The statistical analysis were performed using GraphPad Prism 7.02 software. The non-parametric data 
were analyzed by Kruskal-Wallis analysis for multiple comparisons or by Mann-Whitney analysis for 
analysis of two groups. The significance level was set at 0.05. 
 
Results  
Ovalbumin peptide-loaded liposomes induced OVA-specific antibodies and IgG class switch 
Immunization of BALB/c mice with the peptide- and MPLA-loaded liposomes (Fig. 1A) triggered OVA-
specific IgG isotype switch with production of IgG1, IgG2a, IgG2b, and IgG3 subclasses (Fig. 1B); the 
antibodies were specific also for the individual OVA-derived peptides loaded on the liposomes (data 
not shown). Among the peptide-loaded liposomes, those with the 15mer aa58-72 (OVA2) and the 
17mer aa179-195 (OVA6) were the most immunogenic vaccines. The level of antigen-specific IgG2a 
and IgG2b antibodies secreted was typically comparable to the levels obtained using a TD vaccine 
based on OVA protein and alum. OVA on alum was significantly more immunogenic for IgG1 production 
(p=0.0022), while the OVA2-liposomes induced significantly stronger IgG3 responses (p=0.0043). While 
the protein vaccine stimulated OVA-specific IgE, the liposomal peptide vaccines did not (Fig. 1B). Of 
note, when BALB/c mice were immunized with a single injection of 4 µg soluble OVA2 or OVA6 peptides 
admixed to MPLA-loaded liposomes, no antibody responses could be detected (data not shown). 
Subsequent experiments were done using the OVA2 formulation. 
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A)  
 
 
 
 
 
B) 
 
 
 
 
 
Figure 1: Peptide- and MPLA-loaded liposomes stimulate IgG class switch in vivo. (A) Schematic 
representation of ovalbumin (OVA) peptide- and MPLA-loaded liposomes. The OVA-derived peptide is 
anchored in the liposomal membrane by palmitoyl chains coupled to the side chains of two lysines on both 
ends of the peptide. The adjuvant monophosphoryl lipid A (MPLA) is also integrated in the liposomal 
membrane through its six acyl chains. (B) OVA-specific IgG1, IgG2a, IgG2b, IgG3, and IgE antibodies in sera 
from BALB/c mice immunized on days 0 and 7 with the different peptide-loaded liposomes or OVA protein 
absorbed on alum. Sera was collected on day 14. Arrows indicate sera not reaching the detection limit of OD 
0.1 for a serum dilution of 1/50. Results are expressed as mean + SD (n = 6 per group) and the data are 
representative of four independent experiments with comparable results. ** p< 0.01 calculated by two-
tailed non-parametric Mann-Whitney U test, comparing OVA2-lip and OVA-alum. 
 
Peptide- and MPLA-loaded liposomes stimulated antibody responses independent on T cells 
T-cell deficient athymic nude mice immunized with the OVA2-liposomes produced strong OVA-specific 
antibody responses with immunoglobulin class switch to all IgG subclasses (Fig. 2A). The antibody 
responses were comparable to those determined in immune competent BALB/c mice. To confirm T-
cell independency, MHC class II-deficient mice lacking mature CD4 T cells and TCR-deficient mice 
lacking both αβ and ɣδ T cells were immunized with liposomes, and the induced OVA-specific IgG 
responses were comparable to antibody responses in wild-type C57BL/6 mice (Fig. 2B). The robust 
antibody responses in the T-cell deficient mouse models and the strong IgG2b and IgG3 production 
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demonstrate that both antibody responses and IgG class switch can be obtained in the absence of T 
cells.  
A)  
 
B) 
 
Figure 2: Antibody levels are comparable in wild type and T-cell deficient mice. (A) OVA-specific antibody 
titers measured in sera from athymic nude and BALB/c wild type (WT) mice 6 weeks after immunization with 
OVA2 peptide- and MPLA-loaded liposomes in weeks 0, 1, 2 and 3. (B) Antibody titers in TCR-deficient, MHC 
class II-deficient, and C57BL/6 WT mice measured in sera 7 weeks after immunization with OVA2-loaded 
liposomes in weeks 0 and 1. C57BL/6 mice were immunized in weeks 0, 1, 2 and 3 and serum collected three 
weeks after last immunization. Results are expressed as mean + SD (n = 3 per group). 
 
Immunization with peptide- and MPLA-loaded liposomes triggered fast antigen-specific antibody 
production as well as formation of germinal centers independent on T cells 
The OVA2-liposomes stimulated detectable IgM production within two days of immunization in BALB/c 
mice (Fig. 3A). The IgM response peaked on days 4-6, after which it declined. The IgG1 and IgG3 class 
switch started on day 3, and serum IgG3 kept rising through day 9. The IgG2a and IgG2b serum 
conversion were the slowest with a switch on days 4 to 6, respectively, but both subclasses kept rising 
through day 9.  
Immunization of BALB/c mice with liposomes also caused formation of GCs in the spleens as 
determined by histological PNA (Fig. 3B) and B220 (Fig. 3C) staining in the spleen follicles. The GCs 
were detected five days after immunization and they remained as long as 15 days (not shown). 
Formation of GCs was also observed in athymic nude mice as early as three days after immunization 
with liposomes (Fig. 3D), and these TI-associated GCs remained for at least 10 days (Fig. 3E). The GCs 
induced by peptide-loaded liposomes, in both BALB/c and nude mice, were of comparable size to GCs 
induced by immunization with Qβ VLPs, which were used as a positive control for GC formation. 
However, the number of GCs were generally lower after immunization with liposomes than after VLPs. 
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Flow cytometry analysis of spleens from BALB/c mice confirmed GC formation after immunization and 
revealed increased expression of GL-7-positive CD38-negative B cells compared to naïve mice (Fig. 3F). 
 
Figure 3: Rapid antibody production and long-lived germinal centers independent on T cells. (A) 
OVA-specific antibody levels in BALB/c mice after an intravenous injection of 10 µg OVA2 peptide- 
and MPLA-loaded liposomes. Serum was diluted 1/125 and levels are expressed as mean OD ± SD (n 
= 2 per group). (B-F) Formation of germinal centers after immunization with 10 µg OVA2 liposomes 
or 10 µg Qβ VLPs as a positive control in BALB/c (B, C, F) and nude (D, E) mice. Spleens from BALB/c 
mice were analyzed by immunohistochemical staining with PNA (B) and B220 (C). The OVA2-lip 
treated samples is from day 13 and the positive control from day 5. (D, E) Spleens from nude mice 
were analyzed for germinal center formation by immunofluorescence staining with PNA (red), B220 
(green) and DAPI (blue). The OVA2-lip treated samples are from days 3 (D) and 10 (E), and the 
positive control from a BALB/c mouse on day 10. (F) Representative zebra plots of GL-7 and CD38 
expression on B220 positive BALB/c lymphocytes from day 7. Germinal center cells are defined as 
GL-7 positive and CD38 negative. 
 
 
 
 
Chapter 2 
 
40 
Immunization with peptide- and MPLA-loaded liposomes triggered formation of B-cell memory and 
affinity maturation 
After a single injection of the peptide-loaded liposomes, high levels of antibodies of all IgG subclasses 
were detected in serum for at least 14 weeks, and the antibody longevity was not dependent on T cells 
(Fig. 4A). A strong and T-cell independent IgG boost was observed upon secondary immunization. 
Indeed, the IgG1 antibody responses to peptide-loaded liposomes were higher in nude mice than in 
BALB/c mice, while results from all other subclasses revealed that neither antibody levels nor the 
memory or recall properties were affected by T cells (Fig. 4A). As expected, OVA on alum triggered 
higher levels of IgG1 and IgG2a (Fig. 4B) antibodies than did peptide-loaded liposomes. While IgG2b 
antibody responses were comparable, limited IgG3 boosting was observed after immunization with 
OVA on alum.  
The avidity of antibodies from immunized BALB/c and nude mice was evaluated by competitive ELISA 
as a measure of affinity maturation. The tested sera were collected 1 and 14 weeks after primary 
immunization, and 8-9 weeks after a secondary immunization (weeks 22-23). The avidity of the 
antibodies was measured as the concentration of OVA needed to inhibit 50% of the antibodies from 
binding to plate-coated OVA. Antibodies of higher avidity bind more strongly to OVA, hence, lower 
OVA concentrations are needed for inhibition. The antibody avidity increased from week 1 to week 14 
for all antibody subclasses and all treatment groups (Fig. 4C). A second immunization did not increase 
antibody avidity, despite the strong antibody boosting observed (Fig. 4A-B). The avidity measured for 
antibodies after immunization with OVA on alum was higher than with peptide-loaded liposomes, even 
for the IgG2b and IgG3 (Fig. 4C). The antibody levels (Fig. 4A) as well as avidity (Fig. 4C) were 
comparable in wild type BALB/c and in athymic nude mice following liposomal immunization.  
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Figure 4: Antibodies are long-lived with affinity maturation and B-cell memory responses taking place 
independent on T cells. Production of OVA-specific IgG1, IgG2a, IgG2b and IgG3 antibodies in wild type (WT) 
BALB/C and in nude mice after immunization with (A) 10 µg OVA2 peptide- and MPLA-loaded liposomes or (B) 
100 µg OVA on alum on weeks 0 and 14. Results are expressed as mean ± SEM (n = 5 per group). (C) Avidity of 
IgG1, IgG2a, IgG2b and IgG3 antibodies in sera collected in weeks 1, 14 and 22 (WT) or 23 (nude) analyzed by 
competitive ELISA. 
 
Antibody responses induced by peptide- and MPLA-loaded liposomes displayed characteristics of type 
1 and 2 T cell independent responses 
We further investigated the nature of the second signal for T-cell independent B-cell activation. The 
adjuvant MPLA can bind TLR4 and, in fact, antibody production was completely abrogated in TLR4 
deficient mice (Fig. 5A). The TLR4 signals were transmitted through the adapter molecule MyD88 but 
not through TRIF, as antibody production was abrogated in MyD88- but not in TRIF-deficient mice (Fig. 
5B).  
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In type 2 TI (TI-2) antibody responses, a co-stimulatory signal for B-cell activation comes through the 
cytoplasmic enzyme BTK following extensive cross-linking of the BCRs. We hypothesized that the high 
density of peptides on the liposomal surface could cross-link the BCRs. Indeed, antibody production 
and class-switch was impaired in BTK-deficient mice immunized with the peptide-loaded liposomes 
and only IgM and IgG2a antibodies were detected (Fig. 5C).  
A)  
 
B) 
 
C) 
 
Figure 5: Antibody responses are dependent on TLR4 signaling through MyD88 and partially on BTK. (A) 
OVA-specific antibody titers in (A) wild type (WT) C57BL/6 and TLR4-deficient mice or in (B) MyD88 and TRIF 
deficient mice 6 weeks after two weekly immunizations with the OVA2 peptide- and MPLA-loaded liposomes. 
The WT mice were immunized in weeks 0, 1, 2 and 3 and serum collected in week 6. (C) Antibody titers in WT 
CBA mice and in syngeneic BTK-deficient mice 6 weeks after two weekly immunizations with the OVA2 
liposomes. Arrows indicate sera not reaching the detection limit. Results are expressed as mean + SD (n = 3 
per group). 
 
Antibodies induced with peptide- and MPLA-loaded liposomes are functional and protect mice against 
allergic anaphylaxis 
To test the biological function of antibodies induced by peptide-loaded liposomes, mice were 
immunized, then IgE-sensitized to OVA protein, and finally challenged with a high dose of non-
adjuvanted OVA intraperitoneally (Fig. 6A). Sensitized mice react with an anaphylactic shock 
manifesting as a drop in body temperature. When mice were immunized with peptide-loaded 
liposomes 14 and 10 weeks before the challenge, they reacted with less anaphylactic symptoms and 
less severe temperature drops than did non-immunized mice (Fig. 6B). Indeed, the protection was 
comparable to that obtained in mice immunized with OVA on alum. The maximum average 
temperature drops were 6.2 °C for non-immunized mice, 3.1 °C (OVA on alum) and 3.6 °C (OVA2 
liposomes) for immunized mice. When calculating the integral area above curve (AAC) for the change 
in body temperature and as defined by time-temperature function and the baseline temperature, 
immunization with OVA on alum or peptide-loaded liposomes produced comparable protection (Fig. 
6B, right panel). However, only OVA on alum protected significantly compared to non-immunized mice 
(p=0.0420). 
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To rule out any role of T cells in the observed protection against anaphylaxis, serum from IgE-sensitized 
BALB/c mice was transferred to immunized athymic nude mice twenty hours before the OVA challenge 
(Fig. 6C). The maximum average temperature drop following challenge was 5.3 °C in mice immunized 
with peptide-loaded liposomes, and 8.5 °C in non-immunized mice (Fig. 6D).   
 
  
 
Figure 6: Immunization with peptide- and MPLA-
loaded liposomes reduces susceptibility to 
sensitization independent on T cells. (A) BALB/c mice 
were immunized twice (weeks 0 and 4) with OVA2 
peptide- and MPLA-loaded liposomes or OVA protein 
on alum. In weeks 8 and 11, the mice were subject to 
sensitization by s.c injections of OVA protein on alum. 
An i.p. challenge with soluble OVA was performed in 
week 14. (B) The body temperature upon challenge 
was monitored as a measure for allergic anaphylaxis, 
and the integrated area above curve (AAC) for the 
body-temperature curves was calculated using pre-
challenge temperature as baseline. Results are 
expressed as mean + SEM (n = 5 per group). * p≤ 0.05 
calculated by Kruskal-Wallis test. (C) Nude mice were 
immunized with OVA2 liposomes and boosted 4 
weeks later. In parallel, BALB/c mice were sensitized 
with two s.c injections of 100 µg OVA on alum in 
weeks 0 and 2. In week 7, BALB/c mice were bled and 
sensitized serum was transferred to the immunized 
nude mice; naïve nude mice served as positive 
controls. Challenge was performed 20 hours after 
serum transfer and anaphylaxis tested as described 
above. (D) Body temperatures measured in nude 
mice challenged with OVA and the integrated area 
above curve (AAC) for the body-temperature curves 
was calculated using pre-challenge temperature as 
baseline. Results are expressed as mean + SEM (n = 5 
per group). * p≤ 0.05 calculated by two-tailed non-
parametric Mann-Whitney test. 
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Prophylactic immunization of mice with peptide- and MPLA-loaded liposomes reduces bacterial growth 
in systemic infection of Listeria monocytogenes in vivo 
Since one of the advantages of immunization with T-cell independent vaccines could be the fast onset 
of antibody responses, one could foresee applications in pandemics, where fast and effective 
vaccination coverage is important. Here, mice were immunized with the OVA peptide-loaded 
liposomes and subsequently infected with OVA-expressing L. monocytogenes. Although innate 
immunity and T cells are considered the most important factors controlling listeriosis [232, 233], 
immunized mice displayed significantly diminished bacterial loads in liver (5.2-fold, p=0.0159) as 
compared with infected but non-immunized mice (Fig. 7A). A minor protective effect was also 
determined in the spleen. After immunization with OVA protein on alum, a partial but not significant 
protection was observed. At the time of infection, only OVA-specific IgG1 was detected in sera from 
mice immunized with OVA-alum (Fig. 7B). To evaluate the long-term function of peptide-induced TI 
antibodies, mice were immunized with OVA2 liposomes and infected 6 months later with a lethal dose 
of OVA-expressing L. monocytogenes. Significantly lower number of bacteria were observed in the 
spleen of immunized mice compared to non-immunized mice (p=0.0159) (Fig. 7C). The same, but non-
significant trend was observed for the bacterial load in the liver. At the time of the infection, hence, 
six months after a single injection of the vaccine, positive and high levels of antigen-specific IgG1, 
IgG2a, IgG2b, and IgG3 were determined (Fig.7D). None of the serum IgG subclasses correlated directly 
with bacterial load in organs. 
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Figure 7: Immunization with peptide- and MPLA-loaded liposomes reduces bacterial load in organs after 
Listeria infection. (A-B) Mice were immunized with a mixture of 10 µg OVA2 and OVA6 peptide liposomes or 100 
µg OVA on alum seven days before infection with 10.000 CFU L. monocytogenes expressing OVA. (A) Bacterial 
load in spleen and liver as well as (B) OVA-specific antibodies in blood were determined 48 h after infection and 
one day before infection, respectively. (C-D) Mice were immunized in weeks 0, 4 and 25 with 10 µg OVA2 peptide 
liposomes and infected with 10.000 CFU Listeria in week 28. (C) Bacterial load in spleen and liver as well as (D) 
OVA-specific antibodies in blood were determined 48 h after infection and one day before infection, respectively. 
Results are expressed as mean + SD (n = 5 per group). * p≤ 0.05 calculated by two-tailed non-parametric Mann-
Whitney test. 
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Discussion  
In the current study, we demonstrate that immunization with liposomes loaded with peptide antigens 
and the TLR4 ligand MPLA, stimulated B cells fully independent on T cells. Moreover, the long-lasting 
IgG responses could be boosted months after the primary immunization. To our knowledge, this is the 
first description of in vivo recall memory B-cell responses after immunization with TI peptide antigens. 
The switch to all IgG subclasses took place within four days of immunization in athymic nude mice and 
in mice deficient of αβ and ɣδ T cells or of MHC class II. The antibody responses displayed 
characteristics of both TI-1 and TI-2, since depending on TLR4 signaling through MyD88 and BTK signal 
transmission. GCs formed three days after immunization and were still visible after three weeks, and 
IgG affinity maturation was evidenced by the increased avidity over time. The TI antibodies were found 
to be functional using murine models of allergy and infection.  
TI antigens do not require CD4 TH cells for elicitation of antibody responses. Some TI-1 antigens, such 
as LPS, can stimulate B cells to proliferate in vitro through TLR signaling, resulting in antigen non-
specific antibodies. However, efficient stimulation of antigen-specific antibody responses to TI-1 
antigens require concomitant stimulation of BCRs and TLRs, both in vitro and in vivo [52]. In contrast, 
TI-2 antigens elicit antigen-specific antibody responses through extensive cross-linking of BCRs [63]. 
The simultaneous stimulation of 10-20 BCRs, can be sufficient to activate the B cell in the absence of 
TH cells or other co-stimulatory signals [234, 235]. By these means, repetitive polysaccharide antigens 
on gram-positive bacteria can elicit potent IgM responses but limited class switch in the absence of TH 
cells [10, 61]. Viral envelopes also have highly organized protein structures and can elicit TI IgM and 
IgG antibodies, especially IgG3. However, antibody responses to non-replicating protein antigens, as 
in subunit vaccines, are characterized by IgM antibodies with no class switch to IgG, IgA or IgE in the 
absence of TH cells [202, 236-239]. 
Simultaneous activation of TLRs and BCR further strengthens the B-cell activation and result in SYK-
mediated activation of the NF-κB pathways [114, 202, 240, 241]. MPLA is a detoxified derivative of lipid 
A and LPS, a TLR4 ligand [242], and it is the only adjuvant next to aluminum salts approved for use in 
humans. Our study demonstrates that a high density of peptides and MPLA on liposome surfaces 
provides strong enough signals to activate B cells directly and to induce immunoglobulin class switch 
to all IgG subclasses. The broad distribution of IgG subclasses in response to the peptide-loaded 
liposomes is atypical for TI antibody responses, indicating a thus far unknown mechanism. The TI 
antibody response requires that peptide and MPLA are incorporated into the surface of the same 
individual liposomes ([228] and data not shown), suggesting that peptide and MPLA bind the same B 
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cell and that antigen-presenting cells (APCs) are not involved. Moreover, the limiting parameter for T-
cell independency is peptide density rather than peptide dose. 
TD murine immune responses usually involve all IgG subclasses, but their relative abundance varies as 
a result of the prevailing cytokine environment, which again is affected by interactions of many cell 
populations within the lymphoid tissues [87]. We found that peptide- and MPLA-loaded liposomes 
stimulated a balanced IgG response with expression of all subclasses, while the TD antigen mostly 
elicited IgG1 production. Using liposomes loaded with MPLA and a 15mer amyloid-β peptide [228], we 
were the first to demonstrate IgG class switch with a non-replicating peptide antigen in the absence of 
T cells. However, while liposomes with amyloid-β triggered low levels of IgG2a, IgG2c, and IgG1, 
liposomes with OVA peptides triggered high IgG2a and IgG1 levels. 
The antibody response induced by immunization with the peptide-loaded liposomes displayed 
characteristics of both TI-1 and TI-2 responses. Type 1 TI (TI-1) antigens require TLR signaling to induce 
antibody responses [9]. The adjuvant MPLA can bind to either TLR4 or CD14, both known LPS receptors. 
In the current study, antibody production was abrogated in TLR4 deficient mice, and we already 
showed that antibody responses and IgG class switch was independent of CD14 co-stimulation [228]. 
The antibody responses were unaffected in TRIF-, but abolished in MyD88-deficient mice, as observed 
for the two peptides (OVA2 and OVA6) tested in MyD88- and TRIF-deficient mice. In contrast, 
liposomes loaded with the amyloid-β 1-15 peptide stimulated antibody responses in a TRIF-dependent 
and MyD88-independent manner [228]. It is currently unclear what dictates whether TLR4 utilizes the 
MyD88 or TRIF signaling pathway. In macrophages, CD14-independent signaling by TLR4 was 
dependent on MyD88, whereas CD14-dependent signaling activated TRIF [243]. More recently, initial 
activation on the plasma membrane in macrophages and DCs was found to result in MyD88 signaling 
followed by CD14-dependent endocytosis of TLRs [244], where TRIF signaling subsequently ensues. 
Surface expression of CD14 is limited to myeloid cells, but soluble CD14 can be released and at high 
concentrations substitute for TLR-associated CD14 on other cell types, e.g. B cells [243]. Despite B cells 
being activated through TLRs and playing an essential role in responses to pathogens, most studies on 
the two TLR4 signaling pathways have been performed in DCs and macrophages. In B cells, LPS and its 
immunogenic moiety lipid A have been found to stimulate TLR4 signaling through MyD88 [103, 245, 
246]. In the presence of IL-4, TRIF signaling can become more important [245, 247, 248]. TLR signaling 
stimulated with TD antigens was primarily TRIF dependent [248], indicating that T-cell involvement 
may play a role in the shift to TRIF signaling. However, it remains to be shown whether B cells can 
internalize TLR4 for TRIF signaling and if there is a difference between B cells and myeloid cells in the 
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localization of the TLR4 [245]. Hence, MyD88 and TRIF pathways may play different roles in regulating 
TLR4-induced immune responses in B cells [113]. 
Type-2 TI (TI-2) antigens require intracellular signaling through BTK, following cross-linking of BCRs [9]. 
With the peptide-loaded liposomes, IgM antibody production as well as IgG2a class switch were 
surprisingly normal in BTK-deficient mice, while no class switch to IgG1, IgG2b, and IgG3 was observed. 
Hence, BTK may play distinct roles in class switch to different subclasses.  
Although, TI antigens are not expected to cause GC formation, somatic hypermutation, or B-cell 
memory, immunization with peptide-loaded liposomes enabled T-cell independent GC formation and 
increased IgG avidity. A few studies have reported short-lived GCs in the absence of T cells, but the 
studies used nitrophenyl conjugated to polysaccharide (NP-Ficoll) as antigen in TCRβδ-/- mice [51] and 
transgenic mice with high numbers of NP-specific B cells [52, 53]. We were the first to report IgG class 
switch and GC formation using an amyloid-β-derived peptide and MPLA on liposomes [228].  GCs 
formed in TCR-deficient mice independent of CD28 and CD40L ligation. In the current study with OVA-
derived peptides, we demonstrate that the GCs were T-cell independent and had a long lifespan after 
a single immunization whereas NP-Ficoll-induced GCs were comparably short-lived [52]. In our study 
with OVA peptide-loaded liposomes, TI-associated GCs were marginally smaller and less frequent than 
GCs formed in response to control immunization with TD antigens.  
In TD-associated GCs, T cells are not needed until the stage of centrocyte selection in the light zone, 
after which a proportion of positively selected centrocytes cycles back into the dark zone, as 
centroblasts, for further somatic hypermutation. The centroblasts likely undergo a finite number of 
divisions before they mature into centrocytes, in which case the pool of centroblasts can run out unless 
it is renewed [55]. This could explain the sudden termination of the NP-Ficoll-induced TI GC reaction 
as it collapses by massive B-cell apoptosis a few hours after the dark zone and light zone form, due to 
lack of positive selection and renewal of the centrocyte pool in the absence of TFH cells [53]. 
Interestingly, we found peptide-induced GCs were still visible on day seven in TCR-deficient mice [228], 
as long as 20 days in BALB/c mice, and 10 days in athymic nude mice. More work will be needed to find 
out why GCs survive in the absence of positive selection by antigen-specific T cells, but NF-κB has been 
shown to control GC maintenance and differentiation in TD responses [249], and it is activated by TLR4 
signaling through MyD88 [98, 112]. GCs induced by non-peptide TI antigens are non-functional with 
only limited mutations in transgenic quasimonoclonal mice with unusually strong B-cell signaling [53], 
but not in wild type mice [54]. In contrast, we found increased avidity of each individual IgG subclass 
after immunization with peptide-loaded liposomes. Interestingly, a booster immunization with the 
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alum-adsorbed and T-cell dependent protein vaccines, but not the liposomes, increased the antibody 
avidity further, indicating that affinity maturation is completed earlier for the TI antigen. The biological 
function of the antibodies was demonstrated in vivo in murine model of allergic anaphylaxis and 
Listeria infection. The affinity maturation of B cells can take place both in GCs and, in the absence T 
cells, in the extrafollicular space [27, 250, 251]. In fact, T-cell independent expression of AID, an enzyme 
involved in somatic hypermutation, was observed during B-cell development in a process involving 
both BCRs and TLRs [252]. This result supports a mechanism of action by which peptide- and MPLA-
loaded liposomes, which also induces expression of AID [228], may enable somatic hypermutation and 
affinity maturation independent of CD4 TH cells.  
Antibody responses to the peptide- and MPLA-loaded liposomes have a fast onset and long duration 
with secondary injections giving a memory-like boost in serum IgG. Two days after immunization, IgM 
was detected in sera and the response peaks two days later, in line with responses to the TI antigen 
heat-killed Streptococcus pneumoniae [4]. While the latter study did not detect immunoglobulin class 
switch, we found IgG class switch starting on day 3. In contrast, IgG class switch after immunization 
with TD antigens does not start earlier than on day 6 [71]. Moreover, IgG levels remained high for 
months after immunization with liposomes, and booster immunizations after 7 or 14 weeks 
demonstrated a memory recall response as IgG levels increased beyond the levels determined after 
the primary immunization. To our knowledge, this has never been described for TI peptide antigens. 
Memory B cells have been shown to be inducible with haptenated TI antigens, however, recall antibody 
responses could only be obtained when primed B cells were adoptively transferred to naïve, T-cell 
deficient recipients, before secondary antigen exposure [10, 56, 58-61]. Direct memory response has 
not been shown in the animal it was originally generated in [8], and the TI B-cell memory has been 
found to be regulated through negative feedback by antigen-specific antibodies [59, 61]. A marginal 
increase in IgG antibody-forming cells was reported upon secondary immunization with NP coupled to 
αCD180 antibody in CD40 deficient mice ten weeks after the primary injection [253]. Furthermore, the 
IgG antibody responses was shown to be partially dependent on T cells, as the titers were severely 
impaired in CD40- and TCR-deficient mice and hardly detectable in MHC II-deficient mice [253]. The 
lack of B-cell recall responses in the absence of T cells raises the question how B cells and antibodies 
can be protective upon secondary infection if they are so tightly controlled. In responses to TD 
antigens, a second memory compartment of long-lived bone-marrow plasma cells is generated in 
addition to memory B cells [65, 66]. The bone marrow plasma cells have been believed to be strictly T-
cell dependent and require formation of GCs [67]. Yet, the TI-2 antigen S. pneumoniae capsular 
polysaccharide, generated long-lived bone marrow plasma cells secreting protective IgM and IgG [62]. 
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Nonetheless, the plasma cells generated by TD and TI antigens are functionally different, suggesting 
that the memory plasma cell compartment is heterogeneous [62]. It is unclear when the memory 
compartment comes into play upon secondary exposure to antigen, and the contribution of TI memory 
B cells and TI memory plasma cells may vary depending on antigen type and persistence as well as the 
route of antigen entry. 
Vaccination is the most effective measure to prevent against infections [115]. Protective immune 
responses often correlate with the affinity of neutralizing antigen-specific antibodies, for which reason 
the key to success is the generation of memory B cells [121, 122, 180]. In certain situations, it would 
however be important to stimulate B-cell responses without involvement of T cells. Patients suffering 
from T-cell deficiencies, such as HIV, SCID, DiGeorge or Wiskott-Aldrich syndromes, or the elderly could 
benefit from TI vaccines [254, 255]. Moreover, a TI vaccine could also be used in vaccination against 
self-antigens such as amyloid-β, where it is important to avoid elicitation of cytotoxic T cells that may 
cause unwanted autoimmune tissue damage [256]. TI vaccines may also prove useful in diseases where 
rapid immune protection is needed, but where conventional TD vaccines are not recommended, 
justified, or efficient, e.g. for the protection against pathogens during epidemic infectious outbreaks 
or against bioterrorism [8, 117, 257]. Vaccine strategies without T-cell involvement have not yet been 
explored, because TI peptide antigens have been believed to lack immunoglobulin class switch and 
memory B cells [61]. In light of the growing body of evidence on protective B-cell memory forming 
without CD4 TH cells, the true potential of TI vaccines should be revisited [8, 61, 62, 228]. Here, the 
peptide- and MPLA-loaded liposomes may serve as a useful tool for investigating further the 
characteristics of TI memory and the potential of such immune responses in disease and vaccination.
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Introduction 
Type-I allergic sensitization is the process by which the body produces IgE as response to 
environmental and otherwise inert proteins contained in grass- and tree pollen, animal dander, dust 
mites and more. The sensitization depends on TH2 differentiation of allergen-specific CD4 helper T (TH) 
cells that promote class switch to IgE [157]. While drugs such as antihistamines and corticosteroids 
control peaks of rhino conjunctival symptoms and asthma, allergen immunotherapy (AIT) is the only 
disease-modifying treatment with long-term effects [144]. AIT aims at stimulating a shift from the TH2 
response underlying the allergy, towards a counteracting TH1 response. AIT also stimulates the 
differentiation and production of CD25- and Foxp3-positive CD4 regulatory T cells (TREGs), which play 
an important role in the induction and maintenance of immune tolerance [157]. Finally, AIT leads to a 
re-programming of B cells to produce allergen-neutralizing antibodies, especially of IgG1 and IgG4 
subclasses, and the concomitant suppression of disease-mediating IgE. IgG antibodies are believed to 
prevent allergic responses by binding allergen and thereby obstructing it from cross-linking IgE on 
effector cells [132, 141]. Eventually, these T- and B-cell responses are mechanistically considered to 
provide suppression of allergic inflammation and symptoms. At present, AIT can be obtained by 
subcutaneous (SCIT) or sublingual (SLIT) methods. Both SCIT and SCLIT require multiple administrations 
of allergen over years, for which reason patient compliance is challenging. Moreover, AIT, and 
especially SCIT, is associated with adverse allergic effects because of AIT-allergen reactivity with IgE, 
which in the following can cause mast cell or basophil degranulation [144, 258, 259]. AIT research is 
aimed at simplifying treatment regimens, increasing AIT safety, and enhancing efficacy of AIT [132].  
While CD4 T cells surely influence allergen-specific immune responses and efficacy in AIT, the current 
study addressed the judicious question if the protective effects are not only affected by, but also 
depending on the contribution of T cells. This question is based on the fact that transferred antiserum 
can provide protection against allergic reactions in the host [259, 260]. Moreover, since effective 
protection against anaphylaxis must take place within seconds or minutes of the allergen exposure, 
e.g. as caused by bee or wasp bites, circulating allergen-specific antibodies most likely play an 
important effector role. However, the induction of such effector antibodies during AIT may still be 
strongly regulated by T cells. To test whether T cells are necessary for successful AIT, we applied an 
obligate T-cell independent (TI) vaccine (cf. chapter 2) in the AIT and studied its therapeutic potential 
in a mouse model of anaphylaxis.  
  
 
 
 
On the feasibility of T-cell independent allergen immunotherapy 
 
53 
Methods 
Mice  
BALB/c (BALB/cOlaHsd, H-2d) and athymic nude (Hsd:AthymicNude-Fox1) mice were purchased from 
Envigo (Horst, the Netherlands). The mice were kept and bred under SPF conditions at the animal 
facility of the Biologisches Zentrallabor, University Hospital Zurich. Only female mice were used, and 
all procedures were approved by the animal Research Ethics Board and the Zurich cantonal veterinary 
office (license 98/2014). 
Preparation of peptide liposomes 
Liposomes were prepared from dimyristoyl phosphatidyl choline (DMPC), dimyristoyl phosphatidyl 
glycerol (DMPG), cholesterol (Solvay, Brussels, Belgium), and monophosphoryl lipid A (MPLA; Avanti 
Polar Lipids, Alabaster, USA) as previously described [215]. A short peptide derived from chicken 
ovalbumin (OVA) was used as antigen for formulation in the liposomes. The OVA peptide (OVA aa58-
72; RFDKLPGFGDSIEAQ) was synthesized and flanked with two palmitoylated lysines (Lys) on each 
terminal side (PolyPeptide Laboratories, Strasbourg, France). The liposomes were loaded with 409 
µg/ml peptide and 56 µg/ml MPLA. 
Sensitization and immunotherapy 
Groups of five female BALB/c mice were sensitized subcutaneously (s.c.) at the scruff of the neck with 
full Grade V OVA protein from Sigma-Aldrich (Buchs, Switzerland) mixed with aluminum hydroxide 
(Alum; Alhydrogel 2%) from Brenntag Biosector (Frederikssund, Denmark). OVA was dissolved in 
phosphate-buffer saline (PBS) and allowed to absorb on alum for one hour at room temperature before 
injection.  The sensitization dose was 1 µg OVA and 1 mg alum in 100 µL PBS, and four injections were 
made with weekly intervals.  
T-cell independent AIT was performed with doses of 10 µg OVA peptide and 1.4 µg MPLA on liposomes 
diluted in PBS. T-cell dependent control AIT was performed with a vaccine preparation of 10 µg OVA 
protein on alum. Both vaccines were administered by s.c. injections. The AIT was repeated for a total 
of two or four injections, the time interval between each injection being one, two, or six weeks as 
indicated. A group of control mice were sensitized but did not receive AIT (“No AIT”), while a group of 
challenge control mice were neither sensitized nor received AIT (“Untreated”). 
Blood was collected from tail veins of sensitized and treated mice at different time points, and the 
OVA-specific IgG1, IgG2a, and IgE in serum measured by means of ELISA. 
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Allergen challenge and analysis of systemic anaphylaxis 
Three weeks after the last AIT, 20 or 25 µg OVA in 100 µl PBS was given intraperitoneally (i.p.). This 
challenge causes an anaphylactic reaction in sensitized mice, and the anaphylaxis can be detected as 
a drop in body temperature, as monitored using a digital rectal thermometer (Thermalert TH-5 with a 
RET-3 probe, Physitemp, Huron, NJ). 
Measurement of OVA-specific antibody responses by ELISA 
OVA-specific IgG1, IgG2a, and IgE antibody responses were determined by a sandwich ELISA as 
previously described [226]. Briefly, the plates were coated with 4 µg/ml OVA for IgG subclass detection 
and with 3 µg/ml anti-mouse IgE (AbD Serotec, Düsseldorf, Germany) for detection of IgE. OVA-specific 
IgE was detected using in-house biotin-conjugated OVA, while IgG subclasses were detected with 
biotin-conjugated goat anti-mouse IgG subclass-specific antibodies (Abcam, Cambridge, United 
Kingdom). All plates were developed with streptavidin-conjugated horseradish peroxidase (HRP) and 
with TMB substrate (eBioscience, San Diego, CA, now Thermo Fischer). Reaction was stopped with 2N 
sulphuric acid and absorbance read at 450 nm on a BioTek Instruments plate reader (Winooski, VT). 
The serum concentration of OVA-specific antibodies was calculated against standards for IgG1, IgG2a 
(BioLegend, San Diego, CA) and IgE (AbD Serotec). 
Statistical analysis 
The statistical analysis were performed using the software GraphPad Prism 7.02 software. The non-
parametric data were analyzed by Kruskal-Wallis analysis for multiple comparisons or by Mann-
Whitney analysis for analysis of two groups. The significance level was set at 0.05. 
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Results 
The T-cell dependency of the two AIT 
regimes were first monitored in T-cell 
deficient nude mice. The TI vaccine with 
OVA-peptide and MPLA loaded on 
liposomes induced IgG production in both 
BALB/c and nude mice, while the T-cell 
dependent (TD) vaccine based on alum-
adsorbed OVA protein only stimulated IgG 
antibodies in BALB/c mice (Fig. 1).  
Wild type BALB/c mice were then sensitized and treated with two AIT injections either weekly or 
fortnightly as illustrated in Figure 2A. Sensitized mice, that did not receive AIT showed a hypothermic 
reaction in response to the systemic allergen challenge (Fig. 2B; No AIT). Mice treated with the 
liposomal TI vaccine showed a similar hypothermic reaction to that observed in the otherwise 
untreated allergic mice. In contrast, AIT with the TD vaccine based on OVA and alum provided partial 
protection as seen by reduced hypothermia compared with sensitized control mice (fortnightly AIT, 
p=0.013) and mice treated with the TI vaccine (weekly AIT, p=0.009). Fortnightly AIT with the TI vaccine 
reduced the hypothermic reactions significantly more than weekly treatment (p=0.016). Neither 
weekly nor fortnightly AIT with the TI vaccine had significant effects on the measured hypothermic 
reactions.  
Sensitization induced anti-OVA IgG1, IgG2a, and IgE antibodies, as illustrated for sera collected before 
the first AIT session (Fig. 2C, open bars). During the following five weeks (week 11), the serum levels 
of OVA-specific IgG but not IgE, increased further in the sensitized control mice (Fig. 2C, filled bars). 
AIT with the TI vaccine did not generate a significant boost in serum IgG1 and IgG2a when compared 
to control mice, and IgE levels remained comparable to those measured in sera of sensitized control 
mice. In contrast, AIT with the TD vaccine resulted in an increase in IgG1, IgG2a, and IgE.  
  
 
Figure 1: OVA-specific IgG1 
antibodies in nude and 
BALB/c mice measured by 
ELISA. The mice received 4 
weekly s.c injections of 10 
µg OVA peptide-loaded 
liposomes or 30 µg OVA on 
alum. Blood was collected 
2 weeks after last injection. 
Results are expressed as 
mean + SD (n = 3 per 
group). 
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A)  
 
 
B) 
 
C) 
 
Figure 2: A) Scheme for sensitization 
and AIT with OVA peptide- and MPLA-
loaded liposomes or OVA on alum. The 
mice are sensitized by four weekly s.c 
injections of 1 µg OVA on alum. 
Different groups received two s.c. AIT 
injections in weeks 7 and 8 (weekly) or 
weeks 6 and 8 (fortnightly). Blood was 
collected as indicated. B) The mice 
were challenged with 25 µg OVA i.p. on 
week 11 for analysis of anaphylaxis. C) 
OVA specific IgG1, IgG2a and IgE 
antibodies were measured by ELISA in 
serum from mice receiving weekly and 
fortnightly AIT. Results are expressed as 
mean + SEM (n = 5 per group). ** p< 
0.01, * p≤ 0.05 calculated by Kruskal-
Wallis and Mann-Whitney when 
comparing treatment intervals. 
Next, we tested whether longer AIT time intervals or higher numbers of AIT injections could mediate 
protection against anaphylaxis upon systemic challenge. Mice were sensitized as described above, but 
the AIT interval was increased to six weeks and compared to four fortnightly AIT injections (Fig. 3A). 
AIT with the liposomal TI vaccine produced no protection against allergic anaphylaxis, as the measured 
hypothermic reactions did not differ from that measured in mice that received no AIT (Fig. 3B). In 
contrast, AIT with the TD vaccine produced symptom relief and significantly less hypothermia as 
compared to the sensitized control mice (6-weekly AIT, p= 0.024). However, whether the AIT was 
administered with two- or six-week intervals had no significant effect on the measured hypothermic 
reactions.  
Sensitization induced anti-OVA IgG1, IgG2a, and IgE antibodies, as illustrated for sera collected before 
the first AIT (Fig. 3C, open bars). During the following nine weeks (week 15), the serum levels of OVA-
specific IgG, but not those of IgE, increased further in the sensitized control mice receiving no AIT (Fig. 
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3C, filled bars). AIT with the liposomal TI vaccine did not generate a significant boost in serum IgG1 and 
IgG2a when compared to control mice that did not receive AIT, and the IgE levels remained comparable 
to those measured in sera of sensitized control mice. In contrast, AIT with the TD vaccine resulted in 
an increase in IgG1, IgG2a, and IgE (Fig. 3C).  
A)  
 
 
B)  
 
C)  
 
 
Figure 3: A) Scheme for sensitization 
and AIT with peptide-loaded liposomes 
and OVA on alum. The mice were 
sensitized by four weekly s.c. injections 
of 1 µg OVA on alum. Different 
treatment groups received four s.c AIT 
injections in weeks 6, 8, 10 and 12 or 
two injections in weeks 6 and 12. Blood 
was collected as indicated. B) The mice 
were challenged with 20 µg OVA i.p. in 
week 15 for analysis of anaphylaxis. C) 
OVA specific IgG1, IgG2a and IgE 
antibodies were measured by ELISA in 
serum from mice receiving fortnightly 
and 6-weekly AIT. Results are 
expressed as mean + SEM (n = 5 per 
group). * p≤ 0.05 calculated by Kruskal-
Wallis. 
Since AIT with T-cell independent peptide-loaded liposomes did not protect OVA-sensitized mice 
against allergic anaphylaxis, we tested whether the lack of protection was due to non-efficient AIT or 
due to sensitization potential of the liposome-based treatment itself. Mice received a single injection 
of the liposomal TI vaccine or the alum-based TD vaccine, the doses being 6 µg OVA2 peptide and 100 
µg OVA protein, respectively. While a single injection of the TD vaccine stimulated production of OVA-
specific IgE antibodies, the TI vaccine stimulated no OVA-specific IgE antibodies (Fig. 4A). When 
challenged with a systemic injection of 20 µg adjuvant-free OVA (Fig. 4B), mice that received the TD 
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vaccine OVA on alum reacted with significantly stronger hypothermic reactions than mice that received 
the TI vaccine based on peptide-loaded liposomes (p=0.001). The latter mice showed no temperature 
reaction (Fig 4B) or other monitored anaphylactic symptoms such as piloerection, hunched posture, or 
apathy (not shown).  
A) 
 
B) 
 
Figure 4: A) OVA specific IgE antibodies measured by 
ELISA in serum from mice collected before challenge. B) 
Changes in body temperature after mice were 
sensitized once with peptide-loaded liposomes or 100 
µg OVA on alum and challenged with 20 µg OVA i.p. two 
weeks later for analysis of anaphylaxis.  Results are 
expressed as mean + SEM (n = 5 per group). ** p< 0.01 
calculated by two-tailed non-parametric Mann-
Whitney U test, comparing OVA2-lip and OVA-alum. 
 
Discussion 
In the current study, we investigated whether T cells were required for successful AIT in a mouse model 
of anaphylaxis. Sensitized mice were treated with a T-cell independent (TI) AIT regime of OVA peptide- 
and MPLA-loaded liposomes or with a T-cell dependent (TD) AIT regime based on OVA protein 
adsorbed on alum. Despite stimulating OVA-specific IgG responses, AIT with the TI vaccine provided 
no protection against anaphylactic reactions in OVA-sensitized mice. In contrast, AIT with the TD 
vaccine resulted in a partial relief from hypothermia and other monitored anaphylactic reactions after 
the systemic challenge.  
The serum concentration of IgG4 in humans is an important biomarker for successful AIT [261, 262], 
and IgG2a is considered to have similar effects in mice as IgG4 has in humans [263]. Indeed, AIT with 
the TD vaccine boosted serum IgG2a and gave rise to the strongest relief from allergic symptoms upon 
the systemic challenge for induction of anaphylaxis. Despite the protective efficacy of AIT with the TD 
vaccine, this AIT regime also stimulated a strong increase in the production of OVA-specific IgE when 
compared with the serum levels determined after sensitization alone. However, production of IgE has 
also been reported to increase early in AIT in humans and the serum levels of IgE does not directly 
correlate with the clinical improvement [132, 141, 166]. 
At current, it is not understood why the TI liposomal vaccine, which very efficiently produced high 
titers of allergen-specific IgG1, IgG2a, IgG2b, and IgG3 antibodies in mice (as shown in chapter 2), did 
not protect against systemic anaphylaxis in sensitized mice. This lack of protective efficacy was not a 
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result of an IgE-stimulating and sensitizing potential of the vaccine itself, since its administration did 
not cause induction of allergen-specific IgE or anaphylactic reactions such as hypothermia after a 
systemic allergen provocation. Another explanation for the lack of protective capacity of the TI 
vaccines could be insufficient polyclonality of the induced antibody response. In response to a protein 
antigen, numerous different epitopes on the protein can stimulate production of a diverse repertoire 
of polyclonal antibodies. In contrast, the TI vaccine used in the current study consists of a single short 
peptide, giving a much smaller repertoire of antibodies. Increased polyclonality of the TI antibody 
response may be achieved by attaching different antigen-derived peptides on to the liposomes or by 
administration of different liposomal preparations, each with a different antigen peptide attached. 
Such vaccines would allow for a better evaluation of whether the functional difference is due to 
insufficient polyclonality of the antibody response or the difference in AIT efficacy is due to direct or 
indirect contribution of T cells. Finally, induction of T-cell responses could be required for successful 
AIT. TREGs are important in inducing immune tolerance in AIT and such tolerance not only suppresses 
IgE antibodies and increases IgG. In addition, TREGs suppress cells such as antigen-presenting cells, mast 
cells, basophils and eosinophils as well as interacting with resident tissue cells [132]. To what extent T 
cells convey protection or contribute to protection of AIT has been subject to numerous studies [260, 
264-266]. Transfer of CD4 T cells from immunized mice provides partial protection from anaphylactic 
reaction after challenge in sensitized mice [260]. Furthermore, transfer of CD4 T cells expressing CD25, 
or TREGs, gave more relief from allergic symptoms than did transfer of the CD25 negative population of 
CD4 T cells. However, transfer of whole serum from the immunized mice resulted in nearly complete 
protection. In another study, depletion of TREGs either before or after AIT partially reversed the effects 
of AIT in a mouse model of allergic asthma [264], indicating that TREGs are in part required for the 
induction of tolerance in AIT, but that the T-cell contribution in AIT may vary in the different 
manifestations of allergy. 
The current study also suggested that longer intervals between AIT sessions might be beneficial for the 
outcome of the therapy. When using the TI vaccine, we found that fortnightly AIT produced better 
outcome than did weekly injections. A similar trend was seen for the TD vaccine but the difference was 
not statistically significant. These results are in line with previous reports by us, showing that longer 
intervals between AIT injections improve treatment efficacy [267]. Moreover, general 
recommendations for administration of vaccines include an interval of at least four weeks, and 
vaccination is considered invalid if the recommended injection interval is shortened [268-271]. As 
persistent high doses of antigen may inhibit B cells, longer intervals allow efficient formation of 
memory B cells as well as activation of high affinity T cells [272]. 
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Allergy can manifest with a wide variety of symptoms, such as rhino-conjunctivitis, asthma, 
anaphylaxis, skin rash and hives, and during the elicitation phase of the allergic reactions, the relative 
contribution of potentially protective immune functions varies. Anaphylaxis is perhaps the clinical 
manifestation where we expect allergen-specific IgG antibodies to have the strongest immediate 
protective effect. In the current study, the murine model of anaphylaxis was therefore used to evaluate 
the protective efficacy of allergen-specific IgG generated after AIT with either a TD vaccine or a TI 
vaccine. AIT with TI peptide- and MPLA-loaded liposomes did not protect from anaphylactic reactions 
in sensitized mice in the experimental setup tested, while TD AIT resulted in partial symptom relief. 
However, in this study, serum levels of antibodies did not increase after AIT with the TI vaccine, making 
it difficult to make the conclusion that antibodies alone are not sufficient for successful AIT. In order 
to better compare the relative effects of T and B cells, the polyclonality of the TI antibody response 
would need to be improved. Moreover, the immunoglobulin isotype and IgG subclass distributions as 
well as their serum concentrations and antigen binding affinities, are all confounders that complicate 
a comparison of TD and TI vaccines at the level of mechanism of action. In any case, the strictly T-cell 
independent peptide- and MPLA-loaded liposomal formulation could serve as a novel tool for the 
analysis of the relative contribution of T and B cells in AIT. 
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Allergen-specific subcutaneous (SCIT) as well as sublingual (SLIT) immunotherapy both confer long-
term protection against the highly prevalent IgE-mediated allergies, such as allergic rhino-
conjunctivitis and asthma. Since both SCIT and SLIT are both very laborious and time-consuming 
treatments, we and other have over the last years investigated whether the immunotherapy could be 
enhanced by so-called intralymphatic immunotherapy (ILIT), which aims at improving treatment 
efficacy and safety and to reduce treatment duration, thereby making allergen immunotherapy (AIT) 
more patient friendly. In the original studies made by us [273, 274] and by Cardell et al [275], ILIT was 
administered three times with four week intervals. In 2013, Witten et al. questioned the efficacy of 
ILIT with grass pollen, based on the results of a clinical study of their in 38 adult hay-fever patients 
[276]. While promising immunological changes such as increased IgG4 and Treg responses were 
observed, they concluded that the clinical outcome was at odds with that measured by us in 165 hay 
fever and 20 cat-dander allergic patients as well as in Cardell’s study with 28 hay-fever patients. The 
protocols in these studies differed in one major point. While our and Cardell’s studies used a dosing 
schedule of 4 weeks, Witten’s study utilised a shorter dosing schedule of 2 weeks. We chose the longer 
time intervals based on general vaccine recommendations as they allow build-up of successive waves 
of allergen-specific immune responses with efficient memory B-cell formation and affinity maturation 
without antibody interference. Moreover, CD4 T cells are competing for antigen and that higher 
affinity T cells have a competitive advantage [277]. Of note, no FDA-approved childhood vaccine has a 
shorter time interval than 4 weeks, and the official guidelines consider a vaccination “invalid” if the 
time interval is shortened to less than the recommended minimum.  
Comparably less is known about the role of time intervals in AIT, and especially in newer methods such 
as ILIT. To address this question experimentally, a pre-clinical test in mice was run to investigate the 
effects of varying ILIT dosing intervals on certain characteristics of the antibody response. Groups of 
five female BALB/c mice were sensitised with 1 µg ovalbumin (OVA) adsorbed to aluminium hydroxide 
by four weekly subcutaneous (s.c.) injections. Three weeks later, they received ILIT injections with 10 
µg OVA into the inguinal lymph nodes [156]. The ILIT was repeated for a total of three injections, the 
time interval between each injection being one, two, or four week intervals (Fig.1A). ILIT preparations 
with OVA were made with aluminium hydroxide [156, 226] as this was the adjuvant also used in the 
clinical ILIT trials [273-276]. Blood was collected from tail veins at different time points during the 
study. OVA-specific IgG1, IgG2a, and IgE in serum as well as the OVA-specific affinity of IgG were 
measured at different time points by means of ELISA. 
Sensitisation caused only a weak induction of anti-OVA IgG1 a barely measurable induction of IgG2a, 
but a clear IgE sero conversion (Fig. 1B-D; week 0 versus week 5). Blood IgG1 and IgG2a levels 
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significantly increased in all groups following ILIT, which started on week 6, indicating an effective 
immunotherapy, independent on the time interval between the ILIT sessions. At the end of the study, 
14 weeks after the first of three ILIT injections, the 4-week interval ILIT produced the highest measured 
IgG1 and IgG2a levels, as compared to pre-ILIT antibody levels (Fig. 1E-F). While the IgG1 levels did not 
show correlation between dosing intervals and endpoint antibody levels, the IgG2a levels increased 
with greater time intervals between the ILIT injections (p=0.0355 by Kruskal-Wallis). The former is in 
line with previous reports that show that IgG1 is a less sensitive marker for effective immunotherapy 
in mice than IgG2a [156]. The kinetics of IgG1 antibody production after ILIT showed that 1-week ILIT 
intervals produced a faster IgG1 increase than 2- and 4-week intervals, but that the different ILIT 
protocols later plateaued at comparable serum levels of IgG1 (Fig. 1B). The dynamics of IgG2a antibody 
production over time was less dependent on dosing intervals. IgG2a levels after ILIT with 4-week 
intervals rose as fast as after ILIT with shorter intervals, but reached higher endpoints levels of IgG2a 
(Fig. 1C). IgE production also increased in all groups following ILIT, but the rise followed the same 
pattern and reached the same endpoint antibody levels independent on the ILIT dosing interval (Fig. 
1D and 1G).  
In addition to the titre of antibodies, the affinity of antibodies is an important characteristic for 
assessing the immunological changes following AIT. Therefore, the OVA-specific affinity of total IgG 
and IgG2a was measured using the Martineau ELISA method [278]. A clear increase in both IgG2a and 
total IgG affinity was observed following ILIT and as measured using the Martineau competition ELISA, 
with the biggest rise in IgG2a affinity after 4-weekly ILIT (3.4-fold) followed by 2-weekly (2.8-fold) and 
weekly (2.4-fold) ILIT compared to pre-ILIT affinity values (data not shown). The competition ELISA also 
allowed calculation of the antigen-antibody affinity constant (Ka), which describes the strength of the 
antibody-antigen binding. Table 1 shows the total IgG Ka for sera collected one week after the last ILIT 
or at the study endpoint (10-16 weeks after last ILIT). A clear positive effect of longer ILIT-intervals was 
observed as the Ka increased from 1.0×10-6 M-1 after weekly ILIT, to the 3-fold (2-week ILIT) and 13-
fold (4-week ILIT) as measured 1 week after the last of three ILIT injections. Interestingly, when the 
affinity was measured at the end of the study (week 24), the 2-weeks ILIT produced high-affinity 
antibodies, comparable to those produced during the 4-week ILIT intervals. Hence, the kinetics of the 
affinity maturation seems to be affected by the dosing interval, which again may affect the outcome 
of functional tests performed at different time points after ILIT. The increased affinity with longer 
intervals is probably a result of limited antigen so that only B cells bearing progressively higher affinity 
antibody may continue to be stimulated. In contrast, persistently high doses of antigen have an 
 
 
 
Chapter 4 
 
64 
inhibitory effect on the B cells that are most efficient in trapping antigen. Hence, with low doses and/or 
long dosing intervals, a selective tolerance of high affinity B cells is obtained [272]. 
 
 
  
 
Figure 1. (A) Timeline for 
sensitization, ILIT (triangles), 
affinity antibody measurements 
(circles), and anaphylaxis test. 
Mice were sensitized to OVA by 
weekly s.c. injections and 
subsequently treated in three 
ILIT sessions with 1, 2, or 4 
weeks dosing intervals. IgG1 (B, 
E), IgG2a (C, F) and IgE (D, G) 
antibody responses were 
measured during 20 weeks, with 
the last observation carried 
forward to impute any missing 
values for the 2-week group. (H) 
On week 24, all ILIT mice as well 
as sensitization control mice 
were challenged with OVA in 
saline (i.p.) and the anaphylaxis 
was measured as changes in 
body temperature. The different 
shades of grey in line, symbols, 
and bars represent the different 
dosing intervals, the darker the 
grey, the longer the interval. 
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Table 1. Affinity constant (Ka) of OVA-specific total IgG antibodies as measured one week post last ILIT and at 
the end of the study (16, 14 and 10 weeks after last ILIT). 
 Affinity constant Ka 
Interval 1 wk post ILIT 
(×10-6 M-1) 
Study endpoint 
(×10-6 M-1) 
1 week 1.07 2.96 
2 weeks 3.04 12.3 
4 weeks 12.8 10.8 
 
Additionally, when the protection against experimental anaphylaxis was determined upon challenge 
with a high-dose of allergen in saline given intraperitoneally, differences were observed between the 
different time intervals (P<0.01 by 2-way ANOVA). Briefly, all ILIT-treated mice experienced symptom 
relief as measured by change in body temperature and as compared to sensitised controls that did not 
receive ILIT (Fig. 1H). Partial protection was measured for 1-week ILIT, while more or almost complete 
protection was measured for 2-week ILIT and 4-week ILIT. No significance difference was calculated 
for the two latter. 
In contrast to previous reports on 4-weekly ILIT by us [273, 274] and others [275], Malling’s 
randomised, double-blind, placebo controlled ILIT study showed no significant clinical efficacy of 
weekly or bi-weekly injections based on seasonal hay fever symptoms and medication scores (SMS), 
despite them being reduced [276]. More recently, Patterson et al. have reported positive effect of 4-
weekly ILIT in adolescents and young adults (personal communication), However, intradermal tests 
(IDT) readings and grass pollen skin prick tests (SPT) showed significant reduction in both the treatment 
and the placebo groups, but with no statistically significant difference between groups. Serum 
concentrations of IgG4, an important biomarker for successful AIT [261], increased after grass pollen 
ILIT, with a slightly stronger increase after bi-weekly ILIT than after weekly ILIT. This correlates with 
our findings that longer ILIT intervals results in higher serum IgG2a levels, an antibody subclass 
considered important to murine AIT similar to IgG4 in human AIT [226]. Grass-pollen-specific serum IgE 
levels increased after both bi-weekly and weekly ILIT in the human study by Malling et al. [276], similar 
to what observed in the present murine study, also with no dependency on the ILIT interval. 
In conclusion, ILIT caused a marked rise in IgG1 and IgG2a antibodies independent on the dosing interval. 
However, there was a tendency of stronger antigen-specific IgG antibody responses, especially that of 
IgG2a, with higher affinity after longer ILIT dosing intervals. The same effect was observed in a 
vaccination protocol with one, two, four or eight week immunisation intervals in naïve mice 
(unpublished data). The present study was conducted in mice and the results can, of course, not be 
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directly translated to ILIT in humans. However, the data substantiate the claim that the efficacy of the 
ILIT and perhaps other forms of AIT may depend on the time interval between administrations of the 
therapeutic allergen preparations, similar to that of prophylactic vaccinations against infectious 
diseases in human. We are convinced that correct dosing intervals can improve AIT and that dosing 
interval should be considered and further investigated in future human clinical studies. However, in 
order to collect comparable data from different studies, it is pivotal to apply comparable primary 
outcomes and to estimate clinical efficacy with standardised and generally approved methods. Such 
results are expected to be available in 1-2 years, as the results of several clinical trials will be released, 
all performing ILIT by 3 injections with 4 week intervals. Sang Min Lee and co-workers at Gachon 
University Gil Medical Center are doing animal dander and dust mite ILIT (NCT02301884), Søren Helbo 
SH Skaarup and co-workers at Aarhus University Hospital are doing grass pollen ILIT (NCT02255604), 
Lars-Olof Cardell and co-workers at Karolinska Institutet are doing birch and grass pollen ILIT, and 
Amber Patterson and co-workers at Columbus Nationwide Children's Hospital, are performing grass 
pollen ILIT in 15-24 years old (NCT01982474).  
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Abstract 
One of the greatest pharmaceutical challenges in vaccinology is the delivery of antigens to cytosol of 
antigen-presenting cells (APCs) in order to allow the stimulation of major histocompatibility complex 
(MHC) class I-restricted CD8+ T-cell responses, which may act on intracellular infections or cancer. 
Recently, we described a novel method for cytotoxic T-lymphocyte (CTL) vaccination by combining 
antigens with photosensitiser and light for cytosolic antigen delivery. The goal of the current project 
was to test this immunisation method with particle-based formulations. Liposomes were prepared 
from dipalmitoyl phosphatidylcholine and cholesterol, and the antigen ovalbumin (OVA) or the 
photosensitiser tetraphenyl chlorine disulfonate (TPCS2a) was separately encapsulated. C57BL/6 mice 
were immunised intradermally with OVA liposomes or a combination of OVA and TPCS2a liposomes, 
and light was applied next day for activation of the photosensitiser resulting in cytosolic release of 
antigen from phagosomes. Immune responses were tested both after a prime only regime and after a 
prime-boost scheme with a repeat immunisation two weeks post priming. Antigen-specific CD8+ T-cell 
responses and antibody responses were analysed ex vivo by flow cytometry and ELISA methods. The 
physicochemical stability of liposomes upon storage and light exposure was analysed in vitro. 
Immunisation with both TPCS2a- and OVA-containing liposomes greatly improved CD8+ T-cell 
responses as compared to immunisation without TPCS2a and as measured by proliferation in vivo and 
cytokine secretion ex vivo. In contrast, OVA-specific antibody responses (IgG1 and IgG2c) were reduced 
after immunisation with TPCS2a-containing liposomes. The liposomal formulation protected the 
photosensitiser from light-induced inactivation during storage. In conclusion, the photosensitiser 
TPCS2a was successfully formulated in liposomes and enabled a shift from MHC class II to MHC class I 
antigen processing and presentation for stimulation of strong CD8+ T-cell responses. Therefore, 
photosensitive particulate vaccines may have the potential to add to current vaccine practice a new 
method of vaccination that, as opposed to current vaccines, can stimulate strong CD8+ T-cell 
responses. 
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Introduction 
Current vaccines typically contain colloidal aluminium salts as adjuvants for antigens and elicit efficient 
antibody responses, but only weak T-cell responses, especially those mediated by cytotoxic CD8+ T 
lymphocytes (CTLs). For this reason, current vaccines are typically prophylactic against diseases caused 
by extracellular microbes whose replication can be prevented or their toxins neutralised by 
immunoglobulins. However, intracellular pathogens such as Mycobacteria, Legionella, Brucella, 
Shigella and Leishmania as well as viruses, especially non-cytolytic viruses, may be better controlled 
by cytotoxic CD8+ T lymphocytes capable to recognise and kill infected cells. Similarly, cancer vaccines 
require strong activation of the CD8 arm of immunity, as suggested by studies with subunit vaccines, 
peptide-bearing autologous dendritic cells (DCs), or by adoptive transfer of tumour-specific CD8+ 
lymphocytes [208, 279-286]. When CD8+ T-cell-inducing vaccination has so far been poorly efficient, 
this is ascribed, in part, to inefficient delivery of antigen to the cytosol of antigen presenting cells 
(APCs), a prerequisite for accessing the MHC class I pathway of antigen presentation. For CD8+ T-cell-
inducing vaccination, functionally intact antigen must be transported across several barriers to reach 
intracellular sites of action. Both the plasma and phagosomal membranes impede antigen from 
cytosolic MHC class I processing and presentation [287]. As the efficiency of CD8+ T-cell induction 
furthermore depends on the frequency and duration of antigen presentation by functionally activated 
APCs [288-292], it is likewise important that high doses of vaccine antigen is translocated to the cytosol 
of APCs [293]. Antigens of conventional vaccines typically end up in the MHC class II pathway of antigen 
presentation after maturation and fusion of phagosomes and lysosomes [294-296], a process that 
leads to CD4+ T-helper cell stimulation and antibody production and only minute amounts of antigen 
leaking to cytosol for stimulation of MHC class I-restricted CTLs.  
A number of strategies have been investigated to enhance cellular uptake and cytosolic delivery of 
vaccine antigens. Membrane translocating peptides such the HIV-derived TAT, the HSV-derived VP22, 
or protamine [297-300] can shuffle proteins across plasma membranes. Moreover, as cellular 
membranes possess a net negative charge, cationic liposomes or cationic nano- and microparticles 
have also been used to improve cellular targeting of vaccines [301, 302]. Since vaccines and especially 
vaccine particles normally end up in phagosomes, several strategies have also been implemented to 
trigger antigen release from the phagosomes into the cytosol. For instance, pH-sensitive liposomes 
undergo destabilization and acquire membrane fusogenic properties as pH drops in maturing 
phagosomes, a process that may lead to cytosolic antigen release [303]. The combination of liposomes 
and immune response modifiers or adjuvants has also been suggested for the stimulation of CD8+ T-
cell responses [304, 305]. By the same token, phagosomolytic proteins such as listeriolysin and 
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perfringolysin can be recombinantly integrated in antigens or in vaccine particles in order to facilitate 
cytosolic escape of antigen by lysis of the phagosomal membrane [306-308]. Another antigen delivery 
system that has been shown to stimulate CTLs is ISCOMs or ISCOMATRIX®, which is composed of nano-
sized micelles of saponin, cholesterol, and phospholipids, and whose adjuvancy is in part mediated by 
its fast and efficient draining to lymph nodes [309-311]. As viruses naturally infect the cytosol of cells, 
cytosolic targeting with viral vehicles such as adeno and Vaccinia (MVA) viruses has been widely used 
[312, 313]. Finally, the success of subunit vaccine developments is hardly thinkable without the 
inclusion of immune-response modifiers or adjuvants that provide pathogen-associated (PAMP) and 
danger-associated (DAMP) molecular patterns and signals activating the innate immune system [314-
317] 
Recently, we demonstrated that photosensitisers can be utilised to target soluble antigens to the 
cytosol for stimulation of MHC class I-restricted CD8+ T-cell responses [318-320]. Briefly, we 
hypothesized that a photosensitiser with affinity to cell membrane would translocate to the 
endosomal membrane upon its endocytosis and uptake in APCs. If the photosensitiser is co-delivered 
with the antigen, subsequent light activation of the photosensitiser would cause the generation of free 
radicals, which again would cause damage of the endosomal membrane. As a consequence, the 
endosome would become leaky and thereby release antigen into the cytosol. In the cytosol, the 
antigen would have access to the MHC class I for presentation to and activation of CTLs; Figure 1 
illustrates the concept this so-called PCI (photochemical internalization)-based immunisation. In the 
present study, we applied this technology to a liposome-based formulation in a murine model of 
immunisation. This study showed that combined administration of antigen and photosensitiser in 
liposomes can mediate efficient antigen translocation to the cytosol and thereby enhance CD8+ T-cell 
stimulation.  
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Figure 1. Illustration of PCI-based vaccination with liposomes. Liposome vaccines are taken up by antigen-
presenting cells (APCs) by phagocytosis. Typically, the phagosomes mature and fuse with lysosomes for MHC-II-
restricted presentation of antigen (Ag) peptides to CD4+ T cells. This is also the default presentation pathway of 
vaccines containing photosensitiser (PS), when no light is applied (left scheme). If light is applied (right scheme), 
PS inside the phagosomes will be activated and produce reactive oxygen species that may cause disruption of 
the phagosomal membrane. The now leaky phagosomes release Ag to cytosol, where the proteasomes can digest 
Ag to MHC-I-binding peptides that consequently can be presented to CD8+ T cells. 
 
Methods 
Animals 
Female C57BL/6 mice were purchased from Harlan (Horst, The Netherlands) and used for 
immunisation at the age of 6-7 weeks. Rag2/OT-I mice (B6.129S6-Rag2tm1Fwa Tg(TcraTcrb)1100Mjb) 
from Taconic Europe (Ry, Denmark) were bred in own specific pathogen-free (SPF) facilities at the 
University of Zurich; CD8+ T cells from Rag2/OT-I mice recognise the H-2Kb-restricted epitope SIINFEKL 
from ovalbumin (OVA, aa257-264). All mice were kept under SPF conditions, and the experiments 
performed were approved by a Swiss cantonal veterinary authority (licence 69/2012 from the Zurich 
Vet Office). 
Materials 
The photosensitiser tetraphenyl chlorine disulfonate (TPCS2a) was provided by PCI Biotech (Lysaker, 
Norway) and stored in the dark in a solution containing polysorbate 80, mannitol and 50 mM Tris of 
pH 8,5. Dipalmitoyl phosphatidylcholine (DPPC) was purchased from Lipoid (Ludwigshafen, Germany). 
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Cholesterol, albumin from chicken egg white (OVA; grade V), Triton X-100, RPMI 1640 medium as well 
as red blood cell lysis buffer were from Sigma-Aldrich (Buchs, Switzerland). The SIINFEKL peptide was 
synthesised by ECM microcollections (Tübingen, Germany). H-2Kb/SIINFEKL Pro 5 pentamer was 
bought from Proimmune (Oxford, UK). Fluoraldehyde protein assay reagent (o-phthalaldehyde, OPA) 
was purchased from Thermo Scientific (Reinach, Switzerland). Aluminium hydroxide (Alhydrogel 
adjuvant 2%) was from InvivoGen and purchased from LabForce (Muttenz, Switzerland). 
Preparation of liposomes 
DPPC and cholesterol were separately dissolved in chloroform to a final concentration of 100 mM each 
and stored at -20 °C (stock solutions). For the preparation of liposomes, the stock solutions were mixed 
in molar ratios of 55:45, and chloroform was slowly removed in a rotary evaporator under mild vacuum 
at 40 °C to obtain a homogeneous lipid film after which the lipid film was kept under vacuum overnight. 
The dried film was hydrated and vortexed with a solution of 800 µg/mL of TPCS2a or 200 µg/mL of 
OVA in 10 mM PBS of pH 8 supplemented with 0.006% polysorbate 80. The final lipid concentration 
was 100 mM. Complete hydration of the lipid film and liposome formation was promoted by heating 
the mixture in a water bath at 45 °C. The resulting multilamellar liposomes were made unilamellar by 
six rounds of freeze-thawing and then extruded ten times through polycarbonate membranes of 400 
nm pore size (Steriltech, Kent, USA). 
Characterisation of TPCS2a- and OVA-containing liposomes 
After extrusion, liposomes were separated from the buffer by centrifugal filtration through Amicon® 
Ultra, 0.5 ml, 100k, filters (Merck Millipore, Darmstadt, Germany) for 10 min at 14000 × g. The filters 
were then reversed and spun for 2 min at 1000 × g for recovery of the liposomes. To determine the 
amount of TPCS2a inside the liposomes, the vesicles were destroyed and diluted with a 1% solution of 
Triton-X 100. TPCS2a concentration in the solution was measured fluorimetrically (λex 423 nm, λem 655 
nm; Infinite M200 PRO, Tecan).  
For measuring the OVA content of the liposomes, the separated liposomes were destroyed and diluted 
with a 1% solution of Triton X-100, as described above. The OVA concentration was then measured 
using the OPA assay according to the manufacturer’s instruction. Briefly, 200 µl OPA reagent were 
mixed with 20 μl of OVA solution from the destroyed liposomes, and the mixture transferred to a 
microtiter plate. Fluorescence intensity was measured with a plate reader (infinite® 200 PRO, Tecan, 
Männedorf, Switzerland) at excitation and emission wavelengths of 360 and 455 nm, respectively. OVA 
control standards (5-25 µg/ml) were prepared by dissolving OVA in: (i) water; (ii) Tris buffer of pH 8.5; 
(iii) Triton X-100 (1%); (iv) Triton X-100 (1%) with additional 55 mM DPPC; and (v) PBS of pH 8 to exclude 
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any interference from materials present in the liposomal preparations or used to destroy the 
liposomes.  
Particle size and zeta potential of the liposomes were determined by dynamic light scattering and 
Doppler laser anemometry, respectively, using a DelsaNano C Particle Analyzer (Beckman Coulter, 
Krefeld, Germany). The liposomes were also assesses by cryo-scanning electron microscopy. For this, 
the samples were filled into a 6-mm alu-planchette and sealed with a lid. The samples were frozen in 
a high-pressure freezer (HPM 100, Bal-Tec/Leica, Vienna) and stored in liquid nitrogen. Vitrified 
samples were mounted under liquid nitrogen (-125 °C) on the cryo-holder for freeze-fracturing (BAF 
060, Bal-Tec/Leica) at 1· 10-7 mbar. Coating was performed with 2 nm tungsten at an elevation angle 
of 45° followed by additional 2 nm under continuous elevation angle increase from 45° to 90°. Transfer 
to the precooled cryo-SEM (Zeiss Gemini 1530, Germany) was done under high vacuum (<5 × 
10−7 mbar) with an air-lock shuttle and photographs were taken at -120 °C (VCT Cryostage, Bal-
Tec/Leica) and inlens-SE-signals at 4 kV an acceleration voltage. 
Intradermal immunisation of mice 
Female C57BL/6 mice were immunised as previously described [318]. One day prior to immunisation, 
sex matched Rag2/OT-I spleens and lymph nodes were homogenised, the erythrocytes lysed, and the 
cells washed in PBS before 2×106 cells were administered intravenously into recipient C57BL/6 mice. 
The next day, the fur was shaven off the abdominal region, and 200 µl of the vaccine preparations 
were injected intradermally, which enables subsequent light to reach and activate the photosensitiser; 
deeper subcutaneous or intramuscular injections would not allow efficient light activation of the 
photosensitiser. The vaccine preparations administered were mixtures of 100 µl of OVA-containing 
liposomes with either 100 µl TPCS2a-containing liposomes, or 100 µl soluble TPCS2a (in PBS), or 100 ul 
PBS; mixing was done immediately before administration. The doses of OVA and TPCS2a were 2.5-25 
µg and 100 µg, respectively. In some experiments, control mice received injections with the same 
amount of OVA adsorbed on aluminium hydroxide. After 18 h, all mice were anaesthetised by 
intraperitoneal injection ketamine and xylazine and placed on the LumiSource (PCI Biotech) light 
source for 6 min (4.86 J/cm2) for activation of TPCS2a.  
Analysis of immune responses by flow cytometry and ELISA  
The frequency of antigen-specific CD8+ T cells was monitored in blood and spleen by flow cytometry 
using H-2Kb/SIINFEKL Pro5 pentamer. Cell-surface expression of CD4, CD8, and CD44, and intracellular 
production of IFN-γ were analysed by flow cytometry after Fc-receptor blocking with anti-CD16/32. 
The intracellular staining was done after 6 h incubation at 37 °C with 0.1 μg SIINFEKL. Brefeldin A (2.5 
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μg/ml) was added during the last 4 h. The cells were fixed and permeabilised using BD Perm/Fix as 
described by BD Biosciences (Allschwil, Switzerland), and stained with anti-IFN-γ for 35 min. Pentamer 
staining was performed at 37 °C, all other stainings were performed at 4 °C. All steps were intercepted 
by washing in PBS/FCS 2%. FACS antibodies were from eBioscience (Vienna, Austria) or BD Pharmingen 
(BD Biosciences). Cells were analysed by FACSCanto (BD Biosciences, San Jose, USA), and the data 
evaluated with FlowJo 8.5.2 (Tree Star, Ashland, OR). For the cytokine secretion analysis by ELISA, 
2×105 splenocytes were re-stimulated in round-bottom 96-well plates with 0.1 μg SIINFEKL or 10 ug 
OVA. Supernatants were collected after 24-72 h and analysed using cytokine ELISA ready-set-go kits 
for IL-2 and IFN-γ (eBioscience). 
OVA-specific serum antibodies were analysed using Maxisorb ELISA plates coated with 4 μg/ml OVA. 
IgG1 and IgG2c were detected using biotin-conjugated rat anti-mouse antibodies from BD Pharmingen 
(San Diego, CA) and Abcam (Cambridge, UK), respectively, and the samples were developed using 
strepatavidin-conjugated HRP (BD Pharmingen) and TMB substrate (eBioscience). The optical density 
(OD) at a given serum dilution was measured. 
Analysis of liposome and TPCS2a stability 
The stability of TPCS2a in solution and liposomes was analysed in terms of its fluorescence and as a 
function of light exposure. Light exposure was either to natural daylight (cycles of approx. 12 h light 
and 12 h darkness) or to LumiSource for 1 h (48.6 J/cm2) followed by one daylight/dark cycle of 24 h. 
TPCS2a formulations (approx. 1 ml) were kept in 2 ml clear glass vials with a contact surface to the 
LumiSource of approx. 1 cm2. Non-liposomal TPCS2a was dissolved in in either PBS with 0.006% Tween 
80 or in water, while liposomal TPCS2a was kept in PBS with 0.006% Tween 80. Samples were drawn 
at various time points and assessed fluorimetrically in a plate reader (λex 423 nm, λem 655 nm; Infinite 
M200 PRO, Tecan). In addition, liposomes were also kept at 4 °C in the dark to monitor particle size 
and zeta potential over two weeks.  
Statistics 
The statistical significance of differences between two treatment groups was typically calculated using 
non parametric, 2-tailed Mann-Whitney U tests. When three or more groups were compared, the non-
parametric Kruskal-Wallis test was applied with the Dunn’s multiple comparison post hoc test. To test 
the effect of the photosensitiser in experiments where the vaccines were given as prime only and as 
prime-boost vaccines, a 2-way ANOVA was applied, assuming normally distributed data and 
homogeneity of variances. Significant differences were annotated with asterisks: p<0.05: *; p<0.01: 
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**; p<0.001: ***. Mean and SEM are typically shown. All calculations were done using the GraphPad 
Prism 5.04 software (La Jolla, CA). 
 
Results 
Characterisation of liposomal formulations 
All characteristics of the liposomes are shown in Table 1. The liposome size and size distribution 
remained constant as a function of encapsulation of OVA or TPCS2a, being on average 345-351 nm 
with a polydispersity of 0.09-0.012. Also the zeta potential, which was -6 mV for empty liposomes, 
remained practically unchanged after encapsulation of OVA or TPCS2a. For the liposomes used for later 
immunisation, the content of OVA and TPSC2a were 19.70 or 76.17 µg per mg lipid, respectively. The 
encapsulation efficiency of OVA and TPCS2a were similar and in eh range of 52-55 percent. 
Table 1: Characteristics of the liposomal preparations with OVA or TPCS2a. 
Property Empty liposomes OVA-liposomes TPCS2a-liposomes 
Lipid concentration [mg/ml] 112 112 112 
Size [nm] 347±1 351±1 345±17 
Polydispersity (PDI) 0.12±0.01 0.09±0.03 0.11±0.02 
Zeta potential [mV] -6 -5 -6 
Content of OVA or TPCS2a 
[µg/mg lipid] 
- 19.70a  
1.75b 
76.17 
Encapsulation efficiency [%] - 52.5 ± 3.2 55.0 ± 2.1 
Injected amount of lipids per 
dose (mg)c 
n.a.e 1.269a  
1.425b 
1.313d 
a with 25 µg OVA; b with 2.5 µg OVA; c as used for immunization; d with 100 µg TPCS2a; e not applicable, as empty 
liposomes have not been injected. 
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Impact of liposomal versus soluble photosensitiser 
In a first experiment in vivo, mice were immunised with OVA-containing DPPC:Chol liposomes, OVA-
containing liposomes admixed with soluble TPCS2a, or OVA-containing liposomes mixed with TPCS2a-
containing DPPC:Chol liposomes. The dose of OVA was either 2.5 or 25 µg and that of the 
photosensitiser TPCS2a was fixed at 100 µg. After 6 days, mice were bled by tail bleeding, and the 
blood was analysed for antigen (SIINFEKL)-specific CD8+ T-cell proliferation. Soluble TPCS2a did not 
promote MHC class I-restricted proliferation after immunisation with 2.5 µg liposomal OVA and as 
measured by the frequency of H-2Kb/SIINFEKL pentamer-binding CD8+ T cells in flow cytometry (Fig. 
2A). Both OVA liposomes and OVA liposomes mixed with soluble TPCS2a produced frequencies of 
approx. 2.5-3.0% antigen-specific CD8+ T cells, relative to the total number of CD8+ T cells. When mice 
were immunised with a mixture of OVA liposomes and TPCS2a liposomes, an approximate 4-fold 
increase in the frequency of specific CD8+ T cells was observed. Immunisation with 25 µg OVA in 
liposomes did not cause increased proliferation as compared with immunisation with a tenth of the 
OVA dose (Fig. 2B). However, there was a clear tendency of increased proliferation when the OVA 
liposomes were mixed with soluble TPCS2a and even more so when combined with liposomal TPCS2a 
(Fig. 2B).  
On day 13, the mice were euthanized, and their spleen cells restimulated in vitro with the CD8 epitope 
SIINFEKL (Fig. 2C-D) or with the whole OVA protein (Fig. 2E-F) for analysis of IFN-γ secretion. SIINFEKL-
specific IFN-γ secretion was increased after immunisation with photosensitiser both at low (Fig. 2C) 
and high (Fig. 2D) immunisation doses of OVA. At 2.5 µg OVA, the data revealed a beneficial effect of 
liposomal TPCS2a over soluble TPCS2a, while at 25 µg OVA, both soluble and liposomal TPCS2a 
increased IFN-γ secretion as compared to cells from mice injected with liposomal OVA only. Only 
limited adjuvant effect of co-administered photosensitiser was observed when the cells were re-
stimulated with OVA protein. This was expected, since recall with OVA protein stimulates cytokine 
secretion also from CD4+ T cells, which are not supposed to benefit from TPCS2a. 
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Figure 2. Immunisation with liposomes and photosensitiser. Groups of three mice were immunised with 
liposomes (Lip) containing OVA (open bars), with a mixture of OVA-containing liposomes and soluble 
photosensitiser TPCS2a (grey bars) or with a mixture of OVA-containing and TPCS2a-containing liposomes (black 
bars). The OVA dose was 2.5 (A, C, E) or 25 (B, D, F) µg and the TPCS2a was 100 µg (A-F). One day later, the mice 
were light-treated. On day 6 (A-B), mice were bled, and the frequency CD8+ T cells recognising the H-2Kb-binding 
OVA epitope SIINFEKL was measured by pentamer staining and flow cytometry. On day 13 (C-F), mice were 
euthanized and splenocytes analysed for secretion of IFN-γ after restimulation in vitro with SIINFEKL (C-D) or OVA 
(E-F). The results represent means +SD. No statistical significances were calculated due to the low number of 
replicates (n=3) in this pilot experiment. 
 
Increased antigen proliferation after immunisation with a mixture of antigen-containing liposomes and 
photosensitiser containing liposomes 
Based on this data, further experiments were conducted with 25 µg OVA in liposomes and 100 µg 
TPCS2a in liposomes; both liposomal preparations were mixed within 60 min prior to the injection. In 
addition to an untreated control group, a control group that received OVA adsorbed on aluminium 
hydroxide (OVA-Alum) was included, and selected groups were given a secondary immunisation two 
weeks after priming (Fig. 3A). Proliferation of SIINFEKL-specific CD8+ T cells was observed in blood 7 
days after immunisation with all OVA-containing vaccine formulations, and the cells from immunised 
mice had an activated CD44-expressing phenotype (Fig. 3B). The mean frequency of SIINFEKL-specific 
 
 
 
Chapter 5 
 
78 
CD8+ T cells was 1.41% for liposomal OVA, while the co-administration of TPCS2a-containing liposomes 
significantly enhanced the T-cell response in 8 out of 10 animals yielding a mean frequency of 5.35% 
SIINFEKL specific cells (p<0.001; Fig. 3C). Control immunisation with alum-adsorbed OVA resulted in an 
intermediate proliferation on day 7 after a single immunisation (p<0.05 as compared to immunisation 
with TPCS2a).  
Secondary immunisation of antigen- and photosensitiser containing liposomes caused a strong boost 
of antigen specific CD8+ T-cell proliferation 
Fourteen days after the primary immunisation with liposomal OVA, the two liposome-treated groups 
of ten mice were each split into two subgroups of each five mice; one subgroup received a secondary 
immunisation with the same formulations as before, while the other subgroup did not receive a second 
injection; the OVA-Alum control group also received a booster injection. The boosting with OVA-
containing and TPCS2a-containing liposomes enhanced very strongly the SIINFEKL-specific CD8+ T cells; 
at day 22 (8 days after the booster injection), 17% of all blood CD8+ T cells were SIINFEKL specific (Fig. 
3D). On the contrary, the secondary injection with OVA-containing liposomes without TPCS2a did not 
significantly boost CD8+ T-cell proliferation. For the mice that did not receive a booster dose, the levels 
of SIINFEKL-specific CD8+ T cells at day 22 after priming were significantly higher when they were 
immunised with OVA- and TPCS2a-containing liposomes than with OVA-liposomes only (p=0.0079 by 
Mann Whitney). Immunisation with OVA adsorbed on alum did not notably boost SIINFEKL-specific 
CD8+ T-cell numbers in blood as compared to day 7.  
The longevity of the SIINFEKL-specific CD8+ T-cell responses was tested four weeks after the second 
immunisation sessions (i.e., 6 weeks after priming). As expected, a clear retraction of T cells was 
observed in all groups of animals, with the frequency in mice immunised with TPCS2a-containing 
liposomes decreasing from 17% on day 22 to less than 1% on day 41 (Fig. 3E). However, the relative 
differences between the different immunisation groups was similar to that observed in the earlier 
effector phase, with a clear beneficial effect of TPCS2a-based immunisation also in the memory phase 
of the immune response.  
 
 
 
 
Cytosolic delivery of liposomal vaccines by means of concomitant photosensitisation of phagosomes 
 
79 
 
Figure 3: Antigen-specific proliferation in vivo. (A) Groups of 5-10 mice (5-10) were immunised with OVA-
containing liposomes (OVA-Lip), with OVA-containing liposomes mixed with TPCS2a-containing liposomes 
(TPCS2a-Lip), or with OVA-adsorbed on aluminium hydroxide (OVA-Alum), while negative control mice were left 
untreated. OVA and TPCS2a doses were 25 µg and 100 µg, respectively, in all groups. On day 14, the immunisation 
was repeated for OVA-Alum, while OVA-Lip and the OVA-Lip/TPCS2a-Lip groups were split in two subgroups that 
were re-immunised (n=5) or not (n=5). (B-C) On day 7, mice were bled for analysis of SIINFEKL-specific 
proliferation by pentamer staining and flow cytometry. The same was measured in blood on day 22 (D) and 
spleen cells on day 41 (E). The data represents means + SD. Statistical significance of the difference between 
TPCS2a-treated and TPCS2a-untreated mice were analysed by Mann Whitney (C; p<0.001) and 2-way ANOVA (D-
E), the parameters for the latter being TPCS2a and boost. 
 
Immunisation with antigen- and photosensitiser containing liposomes triggered cytokine production 
On days 22 (in blood; Fig.4A-D) and 41 (in spleens; Fig. 4E-F) after priming, lymphocytes were analysed 
for cytokine production by flow cytometry. Generally, the frequency of cytokine-producing cells was 
higher in mice that received booster injections than in mice that were immunised once only (Fig. 4C-
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F). The strongest boosting effect on IFN-γ and TNF-α-producing CD8+ T cells was observed for mice that 
received TPCS2a-containing liposomes. While the IFN-γ production was maintained or even slightly 
increased over 6 weeks, the TNF-α production was notably lower in the memory phase (day 41) than 
in the effector phase (day 22) of the immune response. Splenocytes harvested on day 41 were also 
restimulated in vitro with SIINFEKL (Fig. 4G) or OVA protein (Fig. 4H) for analysis of cytokine secretion 
by ELISA. Only minor effect of photosensitisation was observed with regards to SIINFEKL-specific IL-2 
secretion, while a strong positive effect of TPCS2a-containing liposomes was observed for the capacity 
to produce IFN-γ and TNF-α (Fig. 4G). Indeed, the effect of photosensitisation on the production of the 
latter two important effector cytokines was comparatively higher than the effect on the number of 
cytokine-producing cells (Fig. 4E-F). For splenocytes re-stimulated with the whole OVA protein, no 
differences in IL-2 and TNF-α secretion were observed between the different treatment groups, but 
the results suggest some effect of photosensitisation on IFN-γ secretion (Fig. 4H). However, the effect 
was not significant and the overall secretion was approx. tenfold lower than measured in cultures of 
cells restimulated with SIINFEKL. Hence, the data once more indicated that TPCS2a provide a CD8-
specific adjuvant effect and not a general effect on T cells. 
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Figure 4: Cytokine secretion in lymphocytes from immunised mice. The mice primed and boosted as described 
in Fig. 3 were analysed for cytokine production by flow cytometry (A-F) and ELISA (G-H). Representative dot blots 
of intracellular IFN-γ (A) and TNF-α (B) producing and CD44+ CD8+ cells are shown. IFN-γ and TNF-α was analysed 
from blood (A-D; day 22) and from spleen cells (E-F; day 41). Spleen cells from day 41 were cultured in vitro with 
SIINFEKL peptide (G) or OVA protein (H), and the concentration of cytokines in the supernatants were analysed 
by ELISA. IL-2 was measured after 24 h and IFN-γ and TNF-α after 72 h. Histograms show means and SEM of 
cytokine producing cells. Hatched bars and filled black bars illustrate groups of mice that received liposomes with 
OVA without and with admixed TPCS2a-containign liposomes, resp. Untreated and Alum-OVA treated mice are 
illustrated with open and grey bars, resp. Statistical significance of the effect of TPCS2a treatment was analysed 
by 2-way ANOVA. 
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Antibody responses were reduced after immunisation with photosensitiser 
Blood was collected and serum made for analysis of anti-OVA antibodies. A single immunisation with 
OVA-containing liposomes produced sero conversion of OVA-specific IgG1 (Fig. 5A) and IgG2c (Fig. 5B) 
as measured on day 41 after primary immunisation. The serum concentrations of both IgG subclasses 
were significantly reduced when mice were immunised with vaccines that also contained the 
photosensitiser TPCS2a (p<0.01 for IgG1 and 0.05 for IgG2c). When mice received a booster injection 
of liposomal OVA, a marked rise in anti-OVA IgG1 was observed. A second injection of liposomal OVA 
and TPCS2a also showed a strong IgG1 increase, with no statistical significant difference being 
observed between mice immunised twice with or without TPCS2a. The immunogenicity of two doses 
with liposomal OVA was also similar to that of two injections with aluminium-adsorbed OVA. The 
serum concentration of IgG2c, an antibody subclass more associated with stronger CD4+ T-cell 
responses, also increased after booster injections, but here, a significant lower concentration was 
measured in mice immunised with TPCS2-containing liposomes than with TPCS2a-free liposomes 
(p<0.05).  
 
Liposomes protected TPCS2a from light-induced inactivation 
The use of liposomes expectedly improved uptake and antigen presentation in vitro with bone-marrow 
derived APCs and IC-21 cells lines (data not shown). To test if the liposomes protected the 
photosensitiser from light-induced inactivation, the change in fluorescent properties was measured 
over time under different light exposition. TPCS2a solutions and liposomal preparations of TPCS2a 
were exposed to daylight, and the natural daylight exposure was interrupted by dark cycles at night; 
control samples were kept light protected throughout the study. No difference in fluorescence was 
observed between liposomal or solute TPCS2a if kept protected from light (Fig. 6A). In the dark, TPCS2a 
fluorescence remained constant for 7 days for the preparations tested. When aqueous and liposomal 
 
Figure 5: Antibody responses in immunised mice. 
The mice primed and boosted as described in Figure 
3 were bled on day 41 for analysis of OVA-specific 
IgG1 (A) and IgG2c (B) antibodies in serum by ELISA. 
Histograms show means and SEM of optical density 
(OD) for 1:100 dilutions of individual sera. Hatched 
and filled black bars show mice that received 
liposomes without or with TPCS2a, respectively. 
Significant differences between groups treated with 
or without TPCS2a were analysed using Kruskal-
Wallis: *: p<0.05; ** p<0.01. 
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TPCS2a samples were exposed to daylight-night cycles, a stronger decay of TPCS2 fluorescence was 
observed for the aqueous photosensitiser solutions in PBS with 0.006% Tween 80. For the latter, 
approx. 15-20% fluorescence loss was measured within 1 day. The decay reached by day 7 a residual 
fluorescence of approx. 40% of the original fluorescence (Fig. 6A). For liposomal TPCS2a preparations, 
the fluorescence decay was less than 5% by day 1, the day 7 residual being approx. 80% of the original 
baseline fluorescence. 
TPCS2a did not cause notable changes in the liposomes’ physicochemical properties  
As a cationic chemical, TPCS2a could also affect the physicochemical stability of the liposomes. Kept 
light-protected at 4 °C, particle size, polydispersity, and zeta potential altered only very slightly over 
13 days storage (Fig. 6B-D). While embedded OVA had no measurable effect on liposome size stability 
over 13 days, TPCS2a caused a slight increase in the size from approx. 345 nm to 375 nm within one 
day, after which the size remained stable (Fig. 6B). The polydispersity index PDI remained similar for 
all three tested preparations, suggesting that size dispersity was not affected by TPCS2a or OVA 
encapsulation (Fig. 6C). Finally, the slightly negative zeta potential of the DPPC:Chol liposomes was not 
affected by TPCS2a or OVA incorporation, the baseline potentials being -6 to -5 mV for all three 
formulations. The cold and dark storage caused no particular change in the zeta potential of OVA-
containing liposomes (Fig. 6D). Both empty and TPCS2a-containing liposomes showed an initial but 
small increase in the zeta potential, but by day 13, the potential lowered again to levels similar to the 
baseline levels, for which reason we conclude that TPCS2a did not compromise storage stability of the 
DPPC:Chol liposomes. 
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In agreement with size and zeta potential data, cryo-SEM micrographs did not reveal noteworthy 
differences in particle morphology between the empty and OVA- or TPCS2a-loaded liposomes nor 
between freshly prepared and stored liposomes (Fig. 7). 
 
Figure 7: Morphology of empty, OVA-containing, and TPCS2a-containing liposomes as visualised by cryo-SEM. 
The liposomes were freshly prepared and frozen after 1 day for cryo-SEM or stored light-protected at 4 °C for 13 
days before processing for cryo-SEM.  
  
 
Figure 6: Stability of empty, TPCS2a-containing 
an OVA-containing liposomes in vitro. (A) 
Aqueous (triangles) or liposomal (circles) 
preparations of TPCS2a were stored in sealed 4 
ml borosilicate glass vials under daylight 
exposure (open symbols) or under darkness 
(filled symbols). Samples were drawn at various 
time points and analysed for TPCS2a-specific 
fluorescence. (B-D) Empty, TPCS2a-containing, 
and OVA-containing liposomes were stored at 4 
°C in the dark and analysed for size (B), size 
distribution (C), and zeta potential (D) as a 
function of time. 
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Discussion 
To cope with this general problem that current vaccines only poorly lead to cross-presentation of MHC 
class I-restricted antigens and stimulation of cytotoxic CD8+ T cells, we recently described a new 
vaccination method of immunisation where antigens are administered in combination with a 
photosensitiser [318-320]. After uptake of antigen and photosensitiser by phagocytosis or endocytosis 
into APCs, light exposure of the site of immunisation leads to disruption of photosensitised 
phagosomes and concomitant release of antigen into cytosol. This process enables antigen to access 
proteasomes for digestion with subsequent loading on MHC-I which precedes export of MHC-I-peptide 
complexes and CD8+ T-cell priming (Fig. 1). The proof of principle of this so-called PCI-based 
immunisation method was ascertained using soluble antigen and photosensitiser. In the current study, 
we formulated the antigen OVA and the photosensitiser TPCS2a in DPPC liposomes in order to test if 
PCI-based immunisation for stimulation of CD8+ T-cell responses could be achieved with vaccine 
particles. 
The results clearly revealed that liposomes can be used for PCI-based cytosolic antigen targeting and 
CD8+ T-cell cross priming. Antigen-specific CD8+ T-cell proliferation improved strongly using TPCS2a-
containing liposomes. This effect was observed after a single immunisation, but especially upon a 
second immunisation, which markedly boosted the long-lasting antigen-specific CD8+ T-cell response, 
with high frequencies of antigen-specific CD8+ T-cells observed in mice at least seven weeks after the 
primary immunisation. In contrast, secondary immunisation with TPCS2a-free liposomes did not 
notably boost CD8+ T-cell responses. Control immunisation with antigen adsorbed on aluminium 
hydroxide showed that this adjuvant, at least in mice and with OVA, was able to mediate some cross 
presentation of antigen, comparable with TPCS2a-free liposomes, but the CD8+ T-cell proliferation was 
clearly inferior to that of PCI-based immunisation with liposomes.  
Similar effects of PCI-based immunisation were observed with regards to the production and secretion 
of the effector cytokines IFN-γ and TNF-α. Both cytokines were up-regulated after immunisation with 
OVA- and TPCS2a-containing liposomes, and the effect was strictly dependent on the photosensitiser. 
In contrast, the production of cytokines after immunisation with aluminium-based vaccine and with 
TPCS2a-free liposomes was more ambiguous. IFN-γ and TNF-α, but not IL-2 secretion was markedly 
lower than after immunisation with the photosensitive vaccines. After restimulation of splenocytes 
with antigen in vitro, both aluminium-based and liposome-based vaccines resulted in high levels of IL-
2 secretion similar to that of PCI-based vaccine. This result fits with the proliferation data as much as 
IL-2 is a growth factor for both CD4+ and CD8+ T-cells and especially needed in the primary expansion 
 
 
 
Chapter 5 
 
86 
phase of the cells [321, 322]. Indeed, high levels of IL-2 were also observed in splenocytes restimulated 
in vitro with the full OVA protein, able to stimulate T cells of several subsets and specificities. The 
relatively low levels in IL-2 after restimulation of splenocytes from mice immunised with PCI-based 
vaccines with SIINFEKL, might be associated with a faster consumption of IL-2 by the more reactive 
and faster proliferating cells from PCI-vaccinated mice.  
While restimulation of splenocytes with the CD8 epitope SIINFEKL showed a clear positive effect of 
PCI-based vaccination in terms of SIINFEKL-specific secretion of IFN-γ and TNF-α, restimulation with 
OVA protein did not significantly distinguish PCI-based vaccines from non-PCI vaccines, nor liposomal 
vaccines from alum-based vaccines. This is most likely due the MHC-II-mediated CD4+ T-cell responses 
stimulated by non-PCI vaccines, but not by PCI-based vaccines, which are thought to act by diverting 
the antigen away from MHC-II processing when the photosensitised phagosomes are photoactivated 
and release their content of antigen into cytosol for MHC-I processing and presentation (Fig. 1). By 
consequence, this would lead to reduced MHC-II-mediated immune responses in vaccinees receiving 
the PCI-based vaccines. Indeed, MHC-II-dependent antibody responses in mice given PCI-based 
vaccines were significantly reduced as compared to mice that received non-PCI liposomal vaccines or 
alum-based vaccines. A single injection of TPCS2a-containing vaccines triggered little IgG1 and IgG2c 
production, while both subclasses were significantly elevated upon a second immunisation session two 
weeks after the first session, suggesting that not all antigen escape MHC class II antigen presentation 
in PCI-based vaccination. This mixed MHC-I and MHC-II presentation might result from antigen and 
photosensitiser being embedded in separate liposomes that may target different antigen presenting 
cells. Only when both antigen and photosensitiser are targeted to the same individual APC, the PCI-
mediated triggering of MHC-I-restricted CD8+ responses is expected. Future studies will need to 
address this question, but technological and analytical issues related to the mixing of the lipids with 
the disulphonated photosensitiser TPCS2a and with a large protein antigen need to be solved first.  
As shown in numerous studies in the last decades, liposomes can target antigens and drugs to 
phagocytic cells such as professional APCs thanks to their particulate nature as well as membrane-
fusogenic properties. Such APC-targeting properties were also aimed for in the current study with 
photoactive liposomal vaccines, but liposomes may potentially also protect photosensitisers from 
light-induced inactivation. This latter would simplify production, storage, and handling of such 
preparations, and it would even prevent premature activation in vivo due to ambient environmental 
light. Indeed, for soluble TPCS2a stored at day light, more than 60% of the compound was lost within 
24 hours as measured by fluorescence. In comparison, liposomal preparations of TPCS2a lost less than 
5% of the fluorescence within 24 hours and only 20% over 7 days. Hence, although it may still be 
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important to assure light protection during storage of TPCS2a-based vaccines, the observations made 
here may suggest a safety benefit of liposomal PCI-based vaccines over soluble PCI-based vaccines. 
 
Conclusion 
The current study demonstrated that PCI-based immunisation technology can be applied to particulate 
vaccines such as liposomes. DPPC liposomes containing the photosensitiser TPCS2a significantly 
improved cross-priming of CD8+ T cells. In addition, the study contributed to the understanding of the 
mechanism of PCI-based immunisation showing a clear diversion of antigen from MHC-II to MHC-I 
processing. Hence, PCI-based vaccines have the potential to add to current vaccine practice a new 
method of vaccination that, as opposed to current vaccines, can stimulate strong CD8+ T-cell 
responses. We expect this method of vaccination to enable treatment and prophylaxis of CD8+ T-cell-
sensitive infections and cancers. Since the photosensitiser TPCS2a, in combination with a cytostatic 
drug, is already approved for clinical trials in humans with cancer (clinicaltrial.gov: NCT01872923, 
NCT00993512, NCT01900158, NCT01606566), the translation of this vaccination modality into clinical 
setting should be facilitated.  
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General discussion and perspectives 
The presented PhD thesis describes the development and the immunological testing of various 
liposomal vaccines for their applicability and capacity to target antigens and adjuvants to specific 
immune cells and cellular compartments. In vaccination and immunotherapy, both T cells and B cells 
play important but distinct roles in forming and providing protective immune responses. Current 
prophylactic vaccines but also therapeutic allergy vaccines, i.e., AIT, require the coordinated 
interaction of APCs, T cells and B cells, and primarily provide protection by eliciting pathogen-, toxin-, 
or allergen-specific antibodies [121-123]. However, due to involvement of these innate and adaptive 
immune cells, the time needed for B-cell activation and secretion of protective serum concentrations 
of antigen-specific, isotype-switched, and high-affinity antibodies is long. In contrast, TI antigens can 
directly stimulate B cells for secretion of antibodies, a reaction that can take place within few days. 
Hence, a vaccine that gives rapid rise to protective levels of antibodies without involvement of T cells 
can be beneficial. Such vaccine strategies have not been systematically explored yet due to lack of 
evidence on TI isotype switch with protein antigens and protective B-cell memory.  
In the last decade, our understanding of TI antigens has grown substantially [8, 61, 62, 228]. Most 
studies on TI immune responses have been performed with polysaccharide antigens or haptenated 
polysaccharides, of no direct clinical relevance. In chapter 2, I describe own studies where peptides 
stimulated class switch and, for the first time, in vivo B-cell memory recall responses in the absence of 
T cells. Such responses were achieved by formulating liposomes with a dense assembly of peptide and 
monophosphoryl lipid A (MPLA) on the surface [202, 228]. The liposomal vaccine directly stimulated B 
cells by a novel immune mechanism with characteristics of both type 1 (TI-1) and type 2 (TI-2) antibody 
responses. Furthermore, the antibody secretion and class switch took place within 2-4 days of 
immunization, and it was associated with formation of long-lived GCs and antibody affinity maturation. 
Such liposomal TI vaccines could serve as a valuable tool for further investigation of TI immune 
responses and a step closer to the realization of TI vaccination. 
Although approximately one third of the world population suffers from allergy due to sensitization to 
environmental proteins, and despite the documented long-term curative effect of AIT [144], AIT is 
taken up by less than 10% of the patients. The poor uptake and treatment compliance are mainly due 
to the risk of treatment-associated side effects and long duration of AIT. Hence, current research 
focuses on increasing safety and enhancing efficacy of AIT. It is well documented that AIT induces both 
B- and T-cell responses, with regulatory CD4 T cells playing an important role in immune tolerance and 
the major effect of IgG antibodies being the neutralization of allergen. However, the relative 
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importance of B- and T-cell responses in AIT is frequently subject to discussions and research [260, 
264, 265]. The facts that transferred antiserum can provide protection against allergic reaction in the 
host [259, 260], and that protection against anaphylaxis must take place within minutes of allergen 
exposure, indicates an important effector role of circulating allergen-specific antibodies, although the 
induction of such antibodies during AIT may still be regulated by T cells. The goal of chapter 3 was to 
use the TI liposomal vaccine described in chapter 2 to address the question if efficacy of AIT was not 
only affected by, but also dependent on the contribution of T cells. The ovalbumin protein adsorbed 
on the adjuvant aluminum hydroxide (alum) was used as TD control vaccine in AIT. The liposomal TI 
vaccine induced high IgG titers in untreated mice by direct stimulation of B cells in chapter 2, yet when 
used in AIT in previously sensitized mice in chapter 3, IgG1 and IgG2a levels in blood did not further 
increase. Additionally, the AIT with the liposomal TI vaccine did not provide relief from anaphylactic 
reactions upon allergen challenge. However, in chapter 2, the TI antibodies were found to have 
neutralizing effects in prophylactic models of allergy and infection. Further studies are needed to 
determine whether this lack of efficacy in AIT is due to the general inability of TI antigens to further 
increase IgG levels in blood or due to T-cell requirement in AIT.  
The results of experiments performed in chapter 3 suggest better AIT efficacy when longer dosing 
intervals between each AIT session were applied. This result is also in line with the conclusion made in 
chapter 4 where higher IgG2a levels, more antibody affinity maturation, and improved protection 
against allergic anaphylaxis was observed when AIT intervals increased in intralymphatic 
immunotherapy (ILIT) in mice. These results are in agreement with clinical observations, showing that 
ILIT was found to reduce effectively allergic symptoms when administered with four-week intervals 
[273-275], but not with two-week intervals [276]. Of note, the general recommendations for 
administration of vaccines include injection intervals of at least four weeks, and vaccination is 
considered invalid if the injection interval is shortened to less than the recommended minimum [268-
271]. As persistent high doses of antigen may have an inhibitory effect on the activation of high-affinity 
B cells, longer vaccination intervals in AIT maintain tolerance of those cells [272]. The daily use of SLIT 
is the current practice and may oppose the concept of long intervals [133]. However, the fact that 
more frequent and higher doses are administered in SLIT than SCIT [133], indicates importance of the 
administration route. Sentinel DCs in the oral mucosa are likely rather prone to induce tolerance than 
to be immune stimulatory. Therefore, the contradiction in SLIT dosing might be explained by the 
evolutionarily conserved mechanism of oral tolerance, which ensures immune tolerance to 
environmental stimuli such as food and commensal bacteria [323]. The research presented in this 
thesis was conducted in mice, for which reason the results cannot be directly translated to humans 
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without further investigation. However, dosing intervals in ILIT affected the immunogenicity and 
treatment efficacy in mice and should be considered in clinical research and practice. 
One of the greatest challenges in vaccinology is the stimulation of cytotoxic CD8 T cell (CTL) responses. 
For this, the antigen must reach the cytosol of APCs, be processed by the proteasome, and loaded on 
MHC class I molecules for presentation to CD8 T cells [182]. As a rule of thumb, vaccine peptide and 
protein antigens are typically processed in phagolysosomes and loaded on MHC class II molecules for 
presentation to CD4 T cells [184]. Recently, our group demonstrated that targeting soluble antigens to 
the cytosol can be achieved with photosensitizers and light, so-called photochemical internalization 
(PCI) [320]. In chapter 5, the cytosolic delivery is further improved by utilizing liposomes to carry the 
photosensitizer and the ovalbumin protein to APCs, resulting in strongly improved antigen-specific CD8 
T-cell proliferation and effector functions. By consequence, the MHC II-mediated immune responses, 
especially antibody response, were considerably reduced. Furthermore, entrapment in liposomes 
protected the photosensitizer from light-induced inactivation upon storage, thereby increasing shelf 
time. Hence, photochemical internalization in combination with liposomes may serve as an effective 
adjuvant in vaccination where strong CD8 T-cell responses are needed, e.g. in cancer and upon 
infection with intracellular pathogens. 
The main limitations of the research presented in this PhD thesis include the demonstration of memory 
responses in chapter 2. Currently, the memory is being measured only as a boost in serum antibodies 
upon secondary immunization and the memory B-cell population not being directly identified. Further 
characterization of the phenotypical and functional features of the population of memory B cells, such 
as the B-cell subtype involved, expressed surface markers etc., would provide information on how 
memory B cells induced with TI antigens differ from those induced with TD antigens. Such knowledge 
would be important for vaccine development and continuing research. Similarly, it remains to be 
determined which signals prevent the GCs from dissipating in the absence of positive selection by T 
cells. In addition, determining the B-cell subsets involved in such GCs as well as whether activation-
induced cytidine deaminase (AID) is expressed, and if affinity maturation takes place in the GCs or 
outside the GCs would be valuable in expanding our general understanding of TI immune responses. 
In chapter 3, avidity of the antibodies induced by different treatments was not compared, although 
the blocking activity of IgG antibodies in AIT may depend on their affinity for the allergen rather than 
quantity of antibodies [132, 141]. As AIT with the liposomal TI vaccine surprisingly did not increase 
antibody levels more than already established during sensitization of mice, it would be interesting to 
see if the avidity of the antibodies improved. Finally, the photosensitizer and ovalbumin could not be 
formulated together in the same liposomal preparation for the studies in chapter 5. Hence, as the 
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concept of photochemical internalization would assume that antigen and photosensitizer reach the 
same APCs, in the current studies, the APCs must simultaneously phagocytose both types of liposomes 
for successful delivery to the cytosol and MHC class I antigen presentation. Nonetheless, concurrent 
uptake of the two types of liposomes appeared to take place as immunization resulted in improved 
CD8 T-cell activation. Perhaps delivery could be enhanced even further with co-delivery of the 
photosensitizer with antigen. Recent work in our group has shown that co-encapsulation of 
photosensitizer and ovalbumin in liposomes is feasible, and immunological studies on the new 
preparations are underway.  
In conclusion, liposomes can be utilized to target peptide antigen to B cells and to activate these 
without any T-cell involvement. In vaccination, patients suffering from T-cell deficiencies such as HIV, 
or T-cell dependent B-cell immunodeficiencies such as common variable immune deficiency (CVID),  or 
patients treated with immune suppressive drugs, or the elderly with aged and inefficient T-cell 
populations could benefit from TI vaccines [255]. Moreover, in vaccination against non-tumor self-
antigens such as amyloid β in Alzheimer’s disease, it is important to avoid elicitation of cytotoxic T cells 
that may cause unwanted autoimmune tissue damage [256]. Also here, TI vaccines may serve a 
valuable purpose. TI vaccines may prove useful in diseases where rapid immune protection and 
immunization coverage is needed, but where conventional TD vaccines are not recommended, 
justified, or not fast or efficient enough, e.g. for the protection of populations against epidemic 
pathogens during infectious outbreaks or against bioterrorism with infectious agents [8, 117, 257].  
The utilization of TI vaccine strategies have not been extensively explored, since TI protein antigens 
have been considered unable to stimulate generation of long-lasting IgG antibodies as well as B-cell 
memory [61]. In light of the growing body of evidence on protective B-cell memory forming without T-
cell help, there is a reason to revisit the true potential of TI vaccines [8, 61, 62, 228]. In this context, 
liposomes represent an attractive option for TI vaccine development as adjuvants and peptide antigens 
can be attached on the liposomal surface with densities sufficient to bypass the need for T-cell help 
[202, 228]. Furthermore, formulating photosensitizer in liposomes has the potential to add new 
options to current vaccine practice by stimulating strong CD8 T-cell responses, for instance in cancer 
immunotherapy or in therapeutic vaccination to fight chronic intracellular pathogens. 
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MZ Marginal zone 
TD T-cell dependent 
TI T-cell independent 
BCR B-cell receptor 
APC Antigen presenting cell 
FDC Follicular dendritic cell 
DC Dendritic cell 
MHC Major histocompatibility complex  
TH T-helper cell 
Ig Immunoglobulin 
IL Interleukin 
IFN Interferon 
PC Plasma cell 
GC Germinal center 
BTK Bruton‘s tyrosine kinase 
TLR Toll-like receptor 
LPS Lipopolysaccharide 
SHM Somatic hypermutation 
CSR Class switch recombination 
TFH Follicular helper T cell 
QM Quasimonoclonal 
BM Bone marrow 
FcR Fc Receptor 
TGF Tumor growth factor 
AID Activation-induced cytidine deaminase 
ADCC Antibody-dependent cellular cytotoxicity 
NK Natural killer 
PAMP Pathogen-associated molecular patterns 
PRR Pattern recognition receptor 
VLP Virus-like particle 
 
 
 
 
 
AIT Allergen immunotherapy 
SCIT Subcutaneous immunotherapy 
SLIT Sublingual immunotherapy 
OIT Oral immunotherapy 
ILIT Intralymphatic Immunotherapy 
Treg Regulatory T cell 
CTL Cytotoxic CD8+ T cells 
MPLA Monophosphoryl lipid A 
DAMP Danger-associated molecular patterns 
OVA Ovalbumin 
PCI Photochemical internalization 
TPCS2a Tetraphenyl chlorine disulfonate 
DPPC Dipalmitoyl phosphatidylcholine 
Chol Cholesterol 
CVID Common varible immune deficiency 
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